



10.04.2019

11:45 - 13:15 ESMO Colloquium supported by Lilly Oncology in collaboration with MSD - How to best use immune checkpoint inhibitors in NSCLC: Single agents or combined with chemotherapy? Room A

Moderation: D. Planchard, Villejuif, FR

11:45 - 11:45 **Session DOI**

11:45 - 11:50 **Introduction**

D. Planchard, Villejuif, FR

11:50 - 12:10 **First-line immunotherapy options for patients without an oncogene driver**

R. Califano, Manchester, GB

12:10 - 12:30 **What is the biological rationale for combining chemotherapy with immune checkpoint inhibitors?**

M. Garassino, Milan, IT

12:30 - 12:50 **Are immune checkpoints (ICPs) better as single agent, doublet ICPs or combined with chemo +/- anti-angiogenics?**

S. Peters, Lausanne, CH

12:50 - 13:10 **Recommendation on second-line treatment according to first-line choice**

D. Planchard, Villejuif, FR

13:10 - 13:15 **Conclusion**

D. Planchard, Villejuif, FR

13:00 - 13:30 Welcome reception

Hall 1



13:30 - 13:45	Opening and welcome	Room B
	Moderation: P. Garrido Lopez ¹ , J. Wolf ² ; ¹ Madrid, ES, ² Cologne, DE	
13:30 - 13:30	Session DOI	
13:30 - 13:35	Welcome to the Congress	
	<u>P. Garrido Lopez</u> ¹ , <u>J. Wolf</u> ² ; ¹ Madrid, ES, ² Cologne, DE	
13:35 - 13:40	Introduction to IASLC	
	<u>G. Scagliotti</u> , Orbassano, TO/IT	
13:40 - 13:45	Introduction to ESMO	
	<u>S. Peters</u> , Lausanne, CH	
13:45 - 14:15	HHH Award lecture	Room B
	Moderation: S. Peters ¹ , G. Scagliotti ² ; ¹ Lausanne, CH, ² Orbassano, TO/IT	
13:45 - 13:45	Session DOI	
13:45 - 14:15	The HHH model applied to radiotherapy: Honour the past, evaluate the present and stimulate the future	
	<u>F. Mornex</u> , Pierre Bénite, FR	



14:30 - 16:00 My patient has stage IIIA (N2) disease: Surgery or radiotherapy? Room B
Moderation: M. Guckenberger¹, S. Zimmermann²; ¹Zürich, CH, ²Lausanne, CH

14:30 - 14:30 **Session DOI**

14:30 - 14:40 **Case presentation**
M. Pless, Winterthur, CH

14:40 - 15:07 **My patient needs neoadjuvant treatment followed by surgery**
W. Eberhardt, Essen, DE

15:07 - 15:34 **My patient needs surgery upfront followed by adjuvant treatment**
M. Pless, Winterthur, CH

15:34 - 16:01 **My patient needs chemoradiotherapy and durvalumab**
D. De Ruyscher, Maastricht, NL

14:30 - 16:00 Current management of early stage NSCLC Room A
Moderation: A.C. Dingemans¹, R. Rami-Porta²; ¹Maastricht, NL, ²Terrassa, Barcelona/ES

14:30 - 14:30 **Session DOI**

14:30 - 14:50 **Early stage lung cancer: Progress in TNM**
R. Rami-Porta, Terrassa, Barcelona/ES

14:50 - 15:10 **Is invasive staging necessary in early stage NSCLC?**
W. Weder, Zurich, CH

15:10 - 15:30 **Current treatment approaches in early disease**
R. Califano, Manchester, GB

15:30 - 15:50 **Early stage lung cancer: The importance of co-morbidity**
A.C. Toffart, La Tronche, FR

15:50 - 16:00 **Q&A**



14:30 - 16:00 Early detection, screening, prevention **Room C**
Moderation: S. Novello¹, N. Peled²; ¹Orbassano, IT, ²Beer Sheva, IL

14:30 - 14:30 **Session DOI**

14:30 - 14:45 **Primary prevention European campaigns**

S. Novello, Orbassano, IT

14:45 - 14:48 **Q&A**

14:48 - 15:03 **e-CIG: Already time to talk about “prevention”?**

C. Dresler, Washington, US

15:03 - 15:06 **Q&A**

15:06 - 15:21 **Low dose CT and secondary prevention: Where we are in Europe**

J. Field, Liverpool, GB

15:21 - 15:24 **Q&A**

15:24 - 15:39 **Early detection of mesothelioma and lung cancer in ultra-high risk populations using a biomarker approach**

T. Behrens, Bochum, DE

15:39 - 15:42 **Q&A**

15:42 - 15:57 **Biomarkers for early detection**

N. Peled, Beer Sheva, IL

15:57 - 16:00 **Q&A**

16:00 - 16:30 Coffee break **Hall 1**



16:30 - 18:00 NSCLC stage IV oncogenic addicted disease Room B
Moderation: E. Felip¹, D. Planchard²; ¹Barcelona, ES, ²Villejuif, FR

16:30 - 16:30 **Session DOI**

16:30 - 16:50 **Current treatment algorithms for EGFR-mutated patients**
F. Cappuzzo, Ravenna, IT

16:50 - 17:10 **Current treatment algorithms for ALK+ and ROS1+ patients**
T. Newsom-Davis, London, GB

17:10 - 17:30 **Targeted therapy beyond EGFR, ALK and ROS1**
D. Planchard, Villejuif, FR

17:30 - 17:50 **Immunotherapy in oncogenic addicted NSCLC**
J. Mazieres, Toulouse, FR

17:50 - 18:00 **Q&A**

16:30 - 18:00 Optimising treatment in stage III Room A
Moderation: W. Eberhardt¹, H. Choy²; ¹Essen, DE, ²Dallas, TX/US

16:30 - 16:30 **Session DOI**

16:30 - 16:50 **Is there only one standard of care in stage III NSCLC?**
P. Garrido Lopez, Madrid, ES

16:50 - 17:10 **Integration of I-O in the management of stage III**
K. Park, Seoul, KR

17:10 - 17:30 **What is the role of surgery for stage III patients in the I-O era?**
P. van Schil, Edegem, BE

17:30 - 17:50 **Innovative radiotherapy approaches for stage III NSCLC patients**
H. Choy, Dallas, TX/US

17:50 - 18:00 **Q&A**



16:30 - 18:15	Proffered Paper session I	Room C
Moderation: A.C. Dingemans ¹ , T. Mitsudomi ² ; ¹ Maastricht, NL, ² Osaka, JP		
16:30 - 16:30	Session DOI	
16:30 - 16:45	680 - Electromagnetic navigation bronchoscopy in the European cohort of the prospective, multicenter NAVIGATE study	
K. Lau ¹ , J. Flandes ² , M. Christensen ³ , M. Bezzi ⁴ , B. Lamprecht ⁵ , M. Salio ⁶ , J.M. Vergnon ⁷ , M. Studnicka ⁸ , M. Trigiani ⁴ , I. Fernandez ² , R. Kropfmüller ⁵ , E. Barisione ⁶ , N. Viby ³ , S. Khandhar ⁹ , E. Folch ¹⁰ ; ¹ London, GB, ² Madrid, ES, ³ Copenhagen, DK, ⁴ Firenze, IT, ⁵ Linz, AT, ⁶ Genova, IT, ⁷ St. Etienne, cédex 2/FR, ⁸ Salzburg, AT, ⁹ Falls Church, VA/US, ¹⁰ Boston, MA/US		
16:45 - 17:00	690 - Comprehensive profiling of genomic and TCR repertoire in localized stage lung adenocarcinomas from a prospective cohort study	
K. Chen, J. Bai, H. Zhao, F. Yang, C. Zhang, Y. Wang, L. Chang, Y. Guan, X. Yi, L. Feng, K. Zhang, S. Cheng, J. Wang; Beijing, CN		
17:00 - 17:15	Invited Discussant 680 and 690	
A. Dingemans, Maastricht, NL		
17:15 - 17:30	830 - Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC	
M. Ouwens ¹ , A. Darilay ² , Y. Zhang ² , P. Mukhopadhyay ³ , H. Mann ⁴ , J. Ryan ⁴ , P. Dennis ² ; ¹ London, GB, ² Gaithersburg, MD/US, ³ Gaithersburg, US, ⁴ Cambridge, GB		
17:30 - 17:45	LBA2 - Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)	
M. Garassino ¹ , L. Paz-Ares ² , R. Hui ³ , C. Faivre-Finn ⁴ , A. Spira ⁵ , D. Planchard ⁶ , M. Ozguroglu ⁷ , D. Daniel ⁸ , D. Vicente ⁹ , S. Murakami ¹⁰ , A. Rydén ¹¹ , Y. Zhang ¹² , C. O'Brien ¹³ , P. Dennis ¹² , S. Antonia ¹⁴ ; ¹ Milan, IT, ² Madrid, ES, ³ Westmead, NSW/AU, ⁴ Manchester, GB, ⁵ Fairfax, US, ⁶ Villejuif, FR, ⁷ Istanbul, TR, ⁸ Chattanooga, US, ⁹ Seville, ES, ¹⁰ Chou-Ku, Tokyo, JP, ¹¹ Mölnådal, SE, ¹² Gaithersburg, MD/US, ¹³ Macclesfield, GB, ¹⁴ Tampa, FL/US		
17:45 - 18:00	LBA4 - Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study	
N. Reinmuth ¹ , B.C. Cho ² , K.H. Lee ³ , A. Luft ⁴ , M. Ahn ² , J. Schneider ⁵ , F. Shepherd ⁶ , S. Geater ⁷ , Z. Pápai-Székely ⁸ , T. Van Ngoc ⁹ , M. Garassino ¹⁰ , F. Liu ¹¹ , D. Clemett ¹² , P. Thiyagarajah ¹² , M. Ouwens ¹³ , U. Scheuring ¹⁴ , S. Peters ¹⁵ , N. Rizvi ¹⁶ ; ¹ Gauting, DE, ² Seoul, KR, ³ Cheongju, KR, ⁴ Saint-Petersburg, RU, ⁵ Mineola, US, ⁶ Toronto, CA, ⁷ Hat Yai, TH, ⁸ Székesfehérvár, HU, ⁹ Ho Chi Minh, VN, ¹⁰ Milan, IT, ¹¹ Gaithersburg, US, ¹² Cambridge, GB, ¹³ London, GB, ¹⁴ Melbourn, GB, ¹⁵ Lausanne, CH, ¹⁶ New York, NY/US		



18:00 - 18:15 **Invited Discussant 830, LBA2 and LBA4**

F. Barlesi, Marseille, CEDEX 20/FR

18:15 - 19:15 Bristol-Myers Squibb - Industry Satellite Symposium

Room A

Moderation: S. Peters, Lausanne, CH

18:15 - 18:20 **Welcome and introductions**

S. Peters, Lausanne, CH

18:20 - 18:45 **Clinical practice today and future considerations**

S. Peters¹, M. Reck²; ¹Lausanne, CH, ²Grosshansdorf, DE

18:45 - 18:45 **Moderator**

H. Borghaei, Philadelphia, US

18:45 - 19:00 **Treating the I-O-experienced patient: Where are we now and where are we headed?**

H. Borghaei, Philadelphia, US

19:00 - 19:00 **Moderator**

S. Peters¹, M. Reck²; ¹Lausanne, CH, ²Grosshansdorf, DE

19:00 - 19:15 **Closing remarks and audience Q&A**

S. Peters, Lausanne, CH



11.04.2019

08:00 - 08:50 Treatment related pneumonitis in lung cancer patients **Room W**
Moderation: K.N. Franks¹, J.G. Aerts²; ¹Leeds, Yorkshire/GB, ²Rotterdam, Noord Brabant/NL

08:00 - 08:00 **Session DOI**

08:00 - 08:15 **The radiation oncology perspective**
K. Franks, Leeds, Yorkshire/GB

08:15 - 08:30 **The respiratory and medical oncology perspective**
J. Aerts, Rotterdam, Noord Brabant/NL

08:30 - 08:50 **Discussion**

08:00 - 08:50 Mini Oral session I **Room A**
Moderation: P. Garrido Lopez¹, E.F. Smit², S. Novello³; ¹Madrid, ES, ²Amsterdam, NL, ³Orbassano, IT

08:00 - 08:00 **Session DOI**

08:00 - 08:05 **1110 - Activity of larotrectinib in TRK fusion lung cancer**
A. Drilon¹, S. Kummar², V. Moreno³, J. Patel⁴, U. Lassen⁵, L. Rosen⁶, B. Childs⁷, S. Nanda⁷, M. Cox⁸, N. Ku⁸, A. Farago⁹; ¹New York, NY/US, ²Stanford, CA/US, ³Madrid, ES, ⁴Chicago, IL/US, ⁵Copenhagen, DK, ⁶Los Angeles, CA/US, ⁷Whippany, NJ/US, ⁸San Francisco, CA/US, ⁹Boston, MA/US

08:05 - 08:10 **1120 - Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)**
L. Horn¹, J. Whisenant¹, H. Wakelee², K. Reckamp³, H. Qiao¹, L. Du¹, J. Hernandez⁴, V. Huang¹, S. Waqar⁵, S. Patel⁶, R. Sanborn⁷, T. Shaffer⁴, K. Garg⁴, A. Holzhausen⁸, K. Harrow⁸, C. Liang⁸, L. Lim⁴, M. Li⁴, C. Lovly¹; ¹Nashville, TN/US, ²Stanford, CA/US, ³Duarte, US, ⁴Kirkland, WA/US, ⁵St. Louis, MO/US, ⁶La Jolla, CA/US, ⁷Portland, OR/US, ⁸Palm Beach Gardens, FL/US

08:10 - 08:15 **1130 - Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001**



L. Paz-Ares¹, R. Doebele², A. Farago³, S. Liu⁴, S. Chawla⁵, D. Tosi³, C. Blakely⁶, J. Krauss⁷, D. Sigal⁸, L. Bazhenova⁹, T. John¹⁰, B. Besse¹¹, J. Wolf¹², T. Seto¹³, E. Chow-Maneval⁹, C. Ye⁶, B. Simmons⁶, G. Demetri³, L. Paz-Ares¹⁴; ¹Sevilla, ES, ²Aurora, CO/US, ³Boston, MA/US, ⁴Washington, DC/US, ⁵Los Angeles, CA/US, ⁶South San Francisco, CA/US, ⁷Ann Arbor, MI/US, ⁸La Jolla, CA/US, ⁹San Diego, CA/US, ¹⁰Heidelberg, VIC/AU, ¹¹Villejuif, CEDEX/FR, ¹²Cologne, DE, ¹³Fukuoka, Fukuoka/JP, ¹⁴Madrid, ES

08:15 - 08:20 **1140 - Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study**

C. Xu¹, W. Wang², Y. Zhu², Z. Yu¹, H. Zhang³, H. Wang⁴, J. Zhang⁴, W. Zhuang¹, T. Lv⁵, Y. Song⁵; ¹Fuzhou, CN, ²Zhenjiang, CN, ³Xi'an, CN, ⁴Beijing, CN, ⁵Nanjing, CN

08:20 - 08:25 **1150 - Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial**

A. Passaro¹, K. Laktionov², A. Poltoratskiy³, I. Egorova³, M. Hochmair⁴, M.R. Migliorino⁵, G. Metro⁶, M. Gottfried⁷, D. Tsoi⁸, G. Ostoros⁹, S. Rizzato¹⁰, G. Mukhametshina¹¹, M. Schumacher¹², S. Novello¹³, R. Dziadziuszko¹⁴, W. Tang¹⁵, L. Clementi¹, A. Cseh⁴, D. Kowalski¹⁶, F. De Marinis¹; ¹Milan, IT, ²Moscow, RU, ³St-Petersburg, RU, ⁴Vienna, AT, ⁵Rome, IT, ⁶Perugia, IT, ⁷Tel Aviv, IL, ⁸Murdoch, WA/AU, ⁹Budapest, HU, ¹⁰Udine, IT, ¹¹Kazan, RU, ¹²Linz, AT, ¹³Orbassano, IT, ¹⁴Gdansk, PL, ¹⁵Ridgefield, CT/US, ¹⁶Warsaw, PL

08:25 - 08:30 **1960 - STELLAR: Final updated results of a phase II trial of TTFIELDS with chemotherapy for unresectable malignant pleural mesothelioma**

G.L. Ceresoli¹, J. Aerts², R. Dziadziuszko³, S. Cedres⁴, B. Hiddinga⁵, J. Van Meerbeeck⁶, M. Mencoboni⁷, D. Planchard⁸, A. Chella⁹, L. Crinò¹⁰, M. Krzakowski¹¹, J. Madrzak³, R. Ramlau¹², F. Grosso¹³; ¹Bergamo, IT, ²Rotterdam, Noord Brabant/NL, ³Gdańsk, PL, ⁴Barcelona, ES, ⁵Groningen, NL, ⁶Edegem, BE, ⁷Genova, IT, ⁸Villejuif, FR, ⁹Pisa, IT, ¹⁰Meldola, (PG)/IT, ¹¹Warsaw, PL, ¹²Poznan, PL, ¹³Alessandria, IT

08:30 - 08:50 **Discussion led by moderators**



09:00 - 10:30 Immunotherapy in stage IV **Room B**
Moderation: E. Felip¹, S. Peters²; ¹Barcelona, ES, ²Lausanne, CH

09:00 - 09:00 **Session DOI**

09:00 - 09:20 **I-O monotherapy**
M. Reck, Grosshansdorf, DE

09:20 - 09:40 **Combo I-O/Chemo**
L. Paz-Ares, Madrid, ES

09:40 - 10:00 **Combo I-O/I-O**
S. Peters, Lausanne, CH

10:00 - 10:20 **Predictive diagnostics and treatment algorithms**
E. Felip, Barcelona, ES

10:20 - 10:30 **Q&A**



09:00 - 10:30 Challenges in clinical oncology: YO case discussions **Room C**
Moderation: R.A. Vidra¹, J. Corral²; ¹Floresti, RO, ²Sevilla, ES

09:00 - 09:00 **Session DOI**

09:00 - 09:05 **Introduction**

R. Vidra¹, J. Corral²; ¹Floresti, RO, ²Sevilla, ES

09:05 - 09:15 **Sequence of ALK patients treatment: A case report**

P. Tarantino, Milan, IT

09:15 - 09:30 **Mentor guided discussion**

B. Besse, Villejuif, CEDEX/FR

09:30 - 09:40 **Role of radiotherapy in oligometastatic I-O progression: A case report**

F. Napolitano, Napoli, IT

09:40 - 09:55 **Mentor guided discussion**

S. Senan, Amsterdam, NL

09:55 - 10:05 **Biomarkers in 1L metastatic NSCLC beyond the PD-L1: A case report**

A. Quilez Cutillas, Cadiz, ES

10:05 - 10:20 **Mentor guided discussion**

E. Arriola Aperribay, Barcelona, ES

10:20 - 10:30 **Q&A**

09:00 - 10:30 Proffered Paper session II **Room A**
Moderation: J. Mazieres¹, U. Malapelle²; ¹Toulouse, FR, ²Napoli, IT

09:00 - 09:00 **Session DOI**

09:00 - 09:12 **210 - EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer**

C. Lindsay¹, F. Blackhall¹, A. Carmel², P. Gazzaniga³, H. Groen⁴, M. Krebs¹, L. Muinelo-Romay⁵, K. Pantel⁶, E. Rossi⁷, L. Terstappen⁸, H. Wikman⁶, J. Soria⁹, F. Farace², A. Renehan¹, C. Dive¹, B. Besse¹⁰, S. Michiels²; ¹Manchester, GB, ²Villejuif, FR, ³Rome, IT, ⁴Groningen, NL, ⁵Santiago De Compostela, ES, ⁶Hamburg, DE, ⁷Padova, IT, ⁸Enschede, NL, ⁹Gaithersburg, CEDEX/US, ¹⁰Villejuif, CEDEX/FR



- 09:12 - 09:24 **1080 - Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)**
M. Lin¹, X. Pan², P. Hou², S. Allen², P. Baumann², M. Hochmair³; ¹Cambridge, US, ²Cambridge, MA/US, ³Vienna, AT
- 09:24 - 09:39 **Invited Discussant 210 and 1080**
J. Wolf, Cologne, DE
- 09:39 - 09:51 **1090 - Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2**
F. Barlesi¹, A. Drilon², F. De Braud³, B.C. Cho⁴, M.J. Ahn⁴, S. Siena³, M. Krebs⁵, C.C. Lin⁶, T. John⁷, D.S.W. Tan⁸, T. Seto⁹, R. Dziadziuszko¹⁰, H. Arkenau¹¹, C. Rolfo¹², J. Wolf¹³, C. Ye¹⁴, T. Riehl¹⁴, S. Eng¹⁴, R. Doebele¹⁵; ¹Marseille, CEDEX 20/FR, ²New York, NY/US, ³Milano, IT, ⁴Seoul, KR, ⁵Manchester, GB, ⁶Taipei, TW, ⁷Heidelberg, VIC/AU, ⁸Singapore, SG, ⁹Fukuoka, Fukuoka/JP, ¹⁰Gdansk, PL, ¹¹London, GB, ¹²Baltimore, MD/US, ¹³Cologne, DE, ¹⁴South San Francisco, US, ¹⁵Aurora, US
- 09:51 - 10:03 **550 - Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation**
S. Wadhwa, G. Krishna.b, M. Malhotra, K. Prabhash, V. Noronha, A. Joshi, V. Patil, A. Mahajan; Mumbai, IN
- 10:03 - 10:15 **1100 - Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts)**
M. Aldea¹, L. Hendriks², L. Mezquita¹, J. Remon-Masip³, D. Planchard¹, C. Jovelet¹, J.C. Benitez³, A. Gazzah¹, C. Naltet¹, P. Lavaud¹, L. Lacroix¹, K. Howarth⁴, C. Morris⁴, E. Green⁴, C. Nicotra¹, B. Besse⁵; ¹Villejuif, FR, ²Maastricht, NL, ³Barcelona, ES, ⁴Cambridge, GB, ⁵Villejuif, CEDEX/FR
- 10:15 - 10:30 **Invited Discussant 1090, 550 and 1100**
U. Malapelle, Napoli, IT
- 10:30 - 11:00 Coffee break** **Hall 1**



11:00 - 12:30 The future of I-O in advanced NSCLC Room A
Moderation: M.C. Garassino¹, S. Zimmermann²; ¹Milan, IT, ²Lausanne, CH

11:00 - 11:00 **Session DOI**

11:00 - 11:20 **Sequencing of I-O therapies**

S. Popat, London, GB

11:20 - 11:40 **Progression on PD1/PD-L1 inhibitors: What is in the pipeline?**

S. Zimmermann, Lausanne, CH

11:40 - 12:00 **Cell-based I-O in NSCLC (TIL, TCRs, CARs, NK): Is there a role?**

J. Aerts, Rotterdam, Noord Brabant/NL

12:00 - 12:20 **Intratumoural I-O: A niche therapy?**

A. Marabelle, Villejuif, FR

12:20 - 12:30 **Q&A / Panel Discussion**

11:00 - 12:30 Current role and future of thoracic radiotherapy Room C
Moderation: S. Senan¹, M. Guckenberger²; ¹Amsterdam, NL, ²Zürich, CH

11:00 - 11:00 **Session DOI**

11:00 - 11:20 **Early stage NSCLC**

M. Guckenberger, Zürich, CH

11:20 - 11:40 **Locally advanced stage NSCLC**

J. Belderbos, Amsterdam, NL

11:40 - 12:00 **Oligometastatic NSCLC**

F. Mornex, Pierre Bénite, FR

12:00 - 12:20 **Synchronous and metachronous primary tumours**

S. Senan, Amsterdam, NL

12:20 - 12:30 **Q&A / Panel Discussion**



11:00 - 12:30 State of art of TMB testing **Room W**
Moderation: M. Pérol¹, M.S. Tsao²; ¹Lyon, CEDEX/FR, ²Toronto, Ontario/CA

11:00 - 11:00 **Session DOI**

11:00 - 11:20 **TMB as predictor of immuno-oncology therapy: The science**
D. Spigel, Nashville, TN/US

11:20 - 11:40 **TMB testing in clinic**
J. Fassunke, Cologne, DE

11:40 - 12:00 **TMB trumps PD-L1 as predictive biomarker for immuno-oncology therapy**
M. Pérol, Lyon, CEDEX/FR

12:00 - 12:20 **PD-L1 is superior to TMB as predictive biomarker for immuno-oncology therapy**
F. Hirsch, New York, CO/US

12:20 - 12:30 **Q&A / Panel Discussion**

11:00 - 12:30 Advances in the surgical management of NSCLC **Room K**
Moderation: A. Brunelli¹, G. Veronesi²; ¹Leeds, GB, ²Rozzano, IT

11:00 - 11:00 **Session DOI**

11:00 - 11:20 **Lobar vs. sublobar resections for stage I NSCLC**
A. Brunelli, Leeds, GB

11:20 - 11:40 **Robotic assisted lung resection for locally advanced lung cancer**
G. Veronesi, Rozzano, IT

11:40 - 12:00 **Quality of life after radical treatment for lung cancer**
C. Pompili, Leeds, GB

12:00 - 12:20 **Intraoperative lymph node dissection in early stage lung cancer: Update on prognostic implications**
D. Lardinois, Basel, CH

12:20 - 12:30 **Q&A / Panel Discussion**



- 12:30 - 13:00 Lunch & Poster Display session** **Hall 1**
- Moderation: B. Besse¹, A.C. Dingemans², D. De Ruyscher², D. Planchard³, N. Peled⁴, R. Buettner⁵, T. Behrens⁶; ¹Villejuif, CEDEX/FR, ²Maastricht, NL, ³Villejuif, FR, ⁴Beer Sheva, IL, ⁵Cologne, DE, ⁶Bochum, DE
- 12:30 - 12:30 **3P - Notable variation of molecular testing in metastatic lung cancer in the Netherlands**
C. Epskamp-Kuijpers¹, M. Van den Heuvel², L. Overbeek³, A. Van Lindert¹, R. Damhuis¹, S. Willems¹; ¹Utrecht, NL, ²Nijmegen, NL, ³Houten, NL
- 12:30 - 12:30 **4P - Correlation between folate receptor alpha (FR α) expression and clinicopathological features in lung adenocarcinoma**
N. Tamura¹, Y. Fujiwara¹, T. Hashimoto¹, H. Shiraishi¹, S. Kitano², T. Shimizu¹, N. Yamamoto¹, N. Motoi¹; ¹Tokyo, JP, ²Tokyo, NY/JP
- 12:30 - 12:30 **5P - The circular RNA circXPO1 promotes tumor growth in lung adenocarcinoma**
Q. Huang, M. Qiu; Beijing, CN
- 12:30 - 12:30 **6P - Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with lung cancer**
C. Son, Busan, KR
- 12:30 - 12:30 **7P - Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models**
U. Weinberg¹, N. Kaynan², T. Voloshin Sela², S. Davidi², Y. Porat², A. Shteingauz², M. Munster², R. Schneiderman², C. Tempel Brami², E. Zeevi², K. Gotlib², S. Cahal², M. Giladi², E. Kirson², A. Kinzel³, Y. Palti²; ¹Luzern, CH, ²Haifa, IL, ³München, DE
- 12:30 - 12:30 **8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)**
M. Drosslerová, M. Šterclová, M. Vašáková, A. Tašková, V. Hytych, P. Horažďovský, E. Richterová, M. Směťáková, L. Havel; Prague, CZ
- 12:30 - 12:30 **9P - Clinical validation of an NGS-based assay for detecting multiple genomic alterations in Chinese patients with non-small cell lung cancer**
H. Ge¹, X. Chen², L. Ruan¹, Q. Gao¹, X. Yang¹, W. Shi¹, X. Li¹, G. Zhu¹; ¹Xiamen, CN, ²Fuzhou, CN
- 12:30 - 12:30 **10P - The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations**
W. Wang¹, C. Xu², Q. Zhang², W. Zhuang², Y. Zhu¹, Z. Huang², G. Chen², M. Fang¹, T. Lv³, Y. Song³; ¹Zhenjiang, CN, ²Fuzhou, CN, ³Nanjing, CN
- 12:30 - 12:30 **11P - Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells**
L. Liang, K. Hui, C. Hu, Y. Wen, X. Jiang; Lianyungang, CN



- 12:30 - 12:30 **12P - Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer**
Q. Zhang¹, C. Xu¹, W. Wang², W. Zhuang¹, Z. Huang¹, G. Chen¹, M. Fang², T. Lv³, Y. Song³; ¹Fuzhou, CN, ²Zhenjiang, CN, ³Nanjing, CN
- 12:30 - 12:30 **13P - The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact**
R. Shemesh¹, Y. Gorzalczany¹, R. Sagi-Eisenberg¹, S. Geva¹, L.R. Roisman², N. Peled²; ¹Tel Aviv, IL, ²Beer Sheva, IL
- 12:30 - 12:30 **14P - The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis**
Y. Zhu¹, C. Xu², W. Wang¹, Q. Zhang², W. Zhuang², G. Chen², M. Fang¹, T. Lv³, Y. Song³; ¹Zhenjiang, CN, ²Fuzhou, CN, ³Nanjing, CN
- 12:30 - 12:30 **15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor**
J.F. Cordoba Ortega¹, A. Salud², S. Morales², J. Veas², A. Rodriguez²; ¹Lleida, ES, ²Lerida, ES
- 12:30 - 12:30 **17P - REDOXI-miRNA of Keap1/Nrf2 axis in lung tumors**
F. Fabrizio, A. Sparaneo, S. Castellana, T. Mazza, D. Trombetta, P. Graziano, A. Rossi, V. Fazio, L.A. Muscarella; San Giovanni Rotondo, IT
- 12:30 - 12:30 **18P - Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features**
E. Kokkotou, V. Rapti, D. Grapsa, P. Bakakos, S. Papadopoulos, M. Bobos, K. Iliadis, K. Syrigos; Athens, GR
- 12:30 - 12:30 **19P - FOXP3³, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer**
H. JIA¹, H. Qi², J. Peng², M. Li², G. Chen¹; ¹Shatin, HK, ²Hong Kong, HK
- 12:30 - 12:30 **20P - Atypical hyperplasia of bronchial epithelial cells induced by chronic exposure to PM 2.5 in mice**
T.F. Hou, Q.H. Chen; Beijing, CN
- 12:30 - 12:30 **22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors**
D. Dumoulin¹, P. de Goeje², M. Poncin², K. Bezemer², H. Groen³, E. Smit⁴, A. Dingemans⁵, A. Kunert², R. Hendriks², J. Aerts⁶; ¹Barendrecht, NL, ²Rotterdam, NL, ³Groningen, NL, ⁴Amsterdam, NL, ⁵Maastricht, NL, ⁶Rotterdam, Noord Brabant/NL



- 12:30 - 12:30 **23P - Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)**
R. Ferrara¹, M. Naigeon², E. Auclin², B. Duchemann³, L. Cassard¹, J.J. Medhi², L. Boselli², J. Grivel², A. Desnoyer², L. Mezquita¹, L. Hendriks⁴, D. Planchard¹, C. Caramella¹, J. Remon-Masip⁵, S. Sangaletti⁶, M. Garassino⁷, B. Besse⁸, N. Chaput⁸;
1Villejuif, FR, 2Paris, FR, 3Bobigny, CEDEX/FR, 4Maastricht, NL, 5Barcelona, ES, 6Milano, IT, 7Milan, IT, 8Villejuif, CEDEX/FR
- 12:30 - 12:30 **24P - A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation**
P. Manca¹, I. Mallona², D. Santini³, G. Tonini³, C. Rolfo⁴, M. Robinson², F. Pantano³;
1Rome, IT, 2Zürich, CH, 3Roma, IT, 4Baltimore, US
- 12:30 - 12:30 **25P - Lung tumorspheres as a drug screening platform against cancer stem cells**
A. Herreros Pomares¹, H. Amado¹, S. Calabuig Fariñas¹, E. Escorihuela¹, J. Murga², S. Torres¹, E. Durendez-Saez¹, F. Zhang¹, A. Blasco¹, A. Navarro¹, C. Sampedro¹, E. Jantus-Lewintre¹, C. Camps¹; 1Valencia, ES, 2Castellón, ES
- 12:30 - 12:30 **26P - Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy**
L. Bonanno, E. Zulato, I. Attili, A. Pavan, P. Del Bianco, G. Nardo, A. Boscolo Bragadin, L. Pasqualini, F. Calabrese, M. Fassan, G. Pasello, V. Guarneri, A. Amadori, P. Conte, S. Indraccolo; Padova, IT
- 12:30 - 12:30 **27P - Comparison of three different gene panels for determination of tumor mutational burden by next generation sequencing**
R. Pappesch, C. Heydt, J. Rehker, S. Merkelbach-Bruse; Köln, DE
- 12:30 - 12:30 **28P - Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients**
S. Calabuig Fariñas, A. Blasco, E. Durendez-Saez, A. Fernández, M. Mosqueda, E. Escorihuela, A. Herreros Pomares, F. Aparisi, J. Garde, M. Shahin, E. Jantus-Lewintre, C. Camps; Valencia, ES
- 12:30 - 12:30 **29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)**
O.J. Juan Vidal, J. Simarro, D. Lorente Estelles, G. Pérez-Simó, N. Mancheno, R. Murria, J. Gomez Codina, B. Laiz, S. Palanca; Valencia, ES
- 12:30 - 12:30 **30P - Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer**
I. Kotsantis, P. Economopoulou, A. Psyrris, E. Maratou, D. Pectasides, H. Gogas, N. Kentepozidis, G. Mountzios, G. Dimitriadis, S. Giannouli; Athens, GR



- 12:30 - 12:30 **31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer**
J. Domagala-Kulawik, T. Skirecki, D. Dziedzic, M. Polubiec-Kownacka, T. Kryczka, I. Kwiecien; Warsaw, PL
- 12:30 - 12:30 **32P - Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers**
E. Durendez-Saez¹, S. Calabuig Fariñas¹, C. Suarez², M. Mosqueda¹, S. Gallach¹, E. Escorihuela¹, A. Moreno¹, N. Dong¹, A. Herreros Pomares¹, E. de la Cueva¹, A. Martinez-Romero¹, E. Serna¹, J.M. Paramio², E. Jantus-Lewintre¹, C. Camps¹; ¹Valencia, ES, ²Madrid, ES
- 12:30 - 12:30 **33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy**
K. Gennen¹, L. Käsmann¹, C. Eze¹, M. Dantes¹, O. Roengvoraphoj¹, J. Taugner², J. Neumann², A. Tufman¹, M. Orth², S. Reu³, C. Belka¹, F. Manapov¹; ¹Munich, DE, ²München, DE, ³Würzburg, DE
- 12:30 - 12:30 **34P - Impacts of HDAC2 inhibition on lung cancer treatment**
Y. Yeh¹, C. Wu², J. Lai², C. Huang², Y. Wei², M. Huang²; ¹Kaohsiung City, TW, ²Kaohsiung, TW
- 12:30 - 12:30 **35P - Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population**
Y. Shen, F. Hu, B. Zhang, B. Han; Shanghai, CN
- 12:30 - 12:30 **36P - Can a BALF profile distinguish hot vs cold lung tumors?**
J. Domagala-Kulawik, D. Dziedzic, M. Polubiec-Kownacka, T. Kryczka, I. Kwiecien; Warsaw, PL
- 12:30 - 12:30 **37P - Genetic variation of lymphotoxin beta receptor (LT β ;R) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals**
F. Dimitrakopoulos¹, A. Antonacopoulou², A. Kottorou¹, V. Tzelepi², N. Panagopoulos², M. Kalofonou³, D. Dougenis², A. Koutras², T. Makatsoris¹, H. Kalofonos²; ¹Patras, Rion/GR, ²Patras, GR, ³London, GB
- 12:30 - 12:30 **38P - Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells**
Y. Liu, R. Kiefl, R. Huber, A. Tufman, D. Kauffmann-Guerrero; Munich, DE
- 12:30 - 12:30 **39P - High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma**
L. Liang, C. Hu, Y. Wen, W. Zhuang, L. Wang, Y. Xia, K. Hui, X. Jiang; Lianyungang, CN



- 12:30 - 12:30 **40P - The metabolic phenotypes of non-small cell lung cancer cells in association with clinical treatment strategies**
T. Kuo¹, T. Hsiao², P. Yang¹; ¹Taipei, TW, ²Taichung, TW
- 12:30 - 12:30 **41P - Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis**
C. Li, Q. He, H. Liang, J. He, W. Liang; Guangzhou, CN
- 12:30 - 12:30 **44P - Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative**
M. Snee¹, S. Cheeseman¹, M. Thompson², M. Riaz¹, L. Lacoïn³, W. Sopwith¹, C. Chaib⁴, M. Daumont⁵, J. Penrod⁶, J. O'Donnell⁶, G. Hall¹; ¹Leeds, GB, ²London, GB, ³Ladeuze, BE, ⁴Madrid, ES, ⁵Braine-L'alleud, BE, ⁶Princeton, NJ/US
- 12:30 - 12:30 **45P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative**
M. Soares¹, L. Antunes¹, P. Redondo¹, M. Borges¹, R. Hermans², D. Patel², F. Grimson², R. Munro², C. Chaib³, L. Lacoïn⁴, M. Daumont⁵, J. Penrod⁶, J. O'Donnell⁶, M. Bento¹, F.R. Goncalves¹; ¹Porto, PT, ²London, GB, ³Madrid, ES, ⁴Ladeuze, BE, ⁵Braine-L'alleud, BE, ⁶Princeton, NJ/US
- 12:30 - 12:30 **46P - Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative**
J. Sørensen¹, S. Ekman², O.T. Brustugun³, P. Horvat⁴, D. Patel⁴, M. Rosenlund², A. Mette Kejs¹, A. Juarez-Garcia⁵, M. Daumont⁶, L. Lacoïn⁷, J. Penrod⁸, J. O'Donnell⁸, M. Planck⁹; ¹Copenhagen, DK, ²Stockholm, SE, ³Oslo, NO, ⁴London, GB, ⁵Uxbridge, GB, ⁶Braine-L'alleud, BE, ⁷Ladeuze, BE, ⁸Princeton, NJ/US, ⁹Lund, SE
- 12:30 - 12:30 **47P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative**
S. Ekman¹, J. Sørensen², O.T. Brustugun³, P. Horvat⁴, D. Patel⁴, M. Rosenlund¹, A. Mette Kejs², A. Juarez-Garcia⁵, M. Daumont⁶, L. Lacoïn⁷, J. Penrod⁸, J. O'Donnell⁸, M. Planck⁹; ¹Stockholm, SE, ²Copenhagen, DK, ³Oslo, NO, ⁴London, GB, ⁵Uxbridge, GB, ⁶Braine-L'alleud, BE, ⁷Ladeuze, BE, ⁸Princeton, NJ/US, ⁹Lund, SE
- 12:30 - 12:30 **48P - Education and lung cancer: A Mendelian randomisation study**
H. Zhou, Y. Zhang, J. Liu, Y. Yang, W. Fang, S. Hong, G. Chen, S. Zhao, Z. Zhang, J. Shen, W. Xian, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN
- 12:30 - 12:30 **49P - A Mendelian randomization study of the effects of Crohn’s disease on lung cancer**
J. Liu, H. Zhou, Y. Zhang, W. Fang, Y. Yang, S. Hong, G. Chen, S. Zhao, J. Shen, W. Xian, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN



- 12:30 - 12:30 **50P - Reduced-, and no-dose thin-section radiologic examinations: Comparison of capability for nodule detection in patients having pulmonary nodules**
W. Tang, Q. Peng, Y. Huang, N. Wu, H. Ouyang; Beijing, CN
- 12:30 - 12:30 **51P - Invasive diagnostic investigation-related complications and its impact on treatment initiation in lung cancer patients in a rapid access lung lesion clinic in regional Australia**
K. Mccann¹, W. Faisal²; ¹Ballarat, VIC/AU, ²Ballarat, AU
- 12:30 - 12:30 **52P - Concordance, decision impact, and satisfaction for a computerized clinical decision support system in treatment of lung cancer patients**
K.A. Lee¹, W. Felix², G. Jackson³; ¹Jupiter, US, ²Boston, MA/US, ³Nashville, TN/US
- 12:30 - 12:30 **53P - Pulmonary tuberculosis: A hurdle to overcome for early lung cancer diagnosis in TB burden countries**
M.S. Akter, S. Ahmed; Dhaka, BD
- 12:30 - 12:30 **56P - CT image standardization is superior to larger but heterogeneous data for robust radiomic models**
D. Vuong¹, M. Bogowicz¹, J. Unkelbach¹, R. Foerster¹, S. Denzler¹, A. Xyrafas², M. Pless³, S. Thierstein², S. Peters⁴, M. Guckenberger¹, S. Tanadini-Lang¹; ¹Zürich, CH, ²Bern, CH, ³Winterthur, CH, ⁴Lausanne, CH
- 12:30 - 12:30 **57P - Non-small cell lung carcinoma (NSCLC) patients with baseline brain imaging: A prospective observational study**
G. NARESH, P.S. Malik, S. Khurana, S. Pathy, M. Yadav, D. Jain, H. Kancharla; New Delhi, IN
- 12:30 - 12:30 **58P - Evaluation of a care path for patients with lung tumors and co-existing interstitial lung disease**
M. Ronden-Kianoush, E. Nossent, C. Dickhoff, S. Nijman, I. Bahce, S. Senan, F. Spoelstra; Amsterdam, NL
- 12:30 - 12:30 **59P - Comparison of internal target volume delineation using CT datasets of four-dimensional computed tomography in lung cancer radiotherapy**
S. Bushra, A. Tibdewal, N. Mummudi, R. Kinhikar, Y. Ghadi, J.P. Agarwal; Mumbai, IN
- 12:30 - 12:30 **60P - Nomogram for patients with stage I small cell lung cancer: A competing risk analysis**
J. Liu, H. Zhou, Y. Zhang, W. Fang, Y. Yang, S. Hong, G. Chen, S. Zhao, X. Chen, Z. Zhang, W. Xian, J. Shen, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN
- 12:30 - 12:30 **61P - Value of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model**
J. Yu, W. Ouyang, J. Hu, J. Zhang, C. Xie; Wuhan, CN



- 12:30 - 12:30 **62P - External validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy**
L. Käsmann¹, R. Abdo², J. Taugner², C. Eze¹, M. Dantes¹, O. Roengvoraphoj¹, C. Belka¹, F. Manapov¹; ¹Munich, DE, ²München, DE
- 12:30 - 12:30 **63P - Real-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients**
M. Hochmair, C. Weinlinger, H. Fabikan, R. Koger, D. Krenbeck, F. Huemer, O. Illini, M. Kulaksiz, A. Valipour, O. Burghuber; Vienna, AT
- 12:30 - 12:30 **64P - Timing of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC)**
L. McSorley¹, C. Goggin², N. Elhadi², P. O'Dea², J. Sui³, D. Kelly³, C. Brady⁴, D. O'Mahony⁴; ¹Galway, IE, ²Cork, IE, ³Dublin, IE, ⁴Cork, Cork/IE
- 12:30 - 12:30 **65P - Experience of prophylactic cranial irradiation in extensive stage small cell lung cancer at a regional cancer center in India**
R. Jat, R. Rai, S. Jakhar, S. Beniwal, N. Sharma, H. Kumar; Bikaner, IN
- 12:30 - 12:30 **66P - Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice**
M. Sebastian¹, F. Barlesi², R. Califano³, A. Mansfield⁴, F. Blackhall³, E. Flahavan⁵, J. Davies⁵, P. Arnold⁶, S. Morris⁶, M. Reck⁷; ¹Frankfurt Am Main, DE, ²Marseille, CEDEX 20/FR, ³Manchester, GB, ⁴Rochester, MN/US, ⁵Welwyn Garden City, GB, ⁶Basel, CH, ⁷Grosshansdorf, DE
- 12:30 - 12:30 **67TiP - ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer**
S. Senan¹, N. Shire², G. Mak³, W. Yao³, H. Jiang⁴; ¹Amsterdam, NL, ²Gaithersburg, US, ³Gaithersburg, MD/US, ⁴Shanghai, CN
- 12:30 - 12:30 **73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries**
R. Damhuis¹, S. Senan², A. Khakwani³, S. Harden⁴, A. Helland⁵, T. Strand⁵; ¹Utrecht, NL, ²Amsterdam, NL, ³Nottingham, GB, ⁴Cambridge, GB, ⁵Oslo, NO
- 12:30 - 12:30 **74P - Is there any prognostic significance of the level of change in SUVmax after SBRT in patients with early stage NSCLC?**
G. Yaprak¹, A. Ozen², F. Tugrul², S. Ozugur¹, N. Isik¹; ¹Istanbul, TR, ²Eskisehir, TR
- 12:30 - 12:30 **75P - Thoracic ultrasound can be a trustable tool in untouchable lung nodule surgery**



H. Zhang, Berlin, CN

- 12:30 - 12:30 **76P - Endobronchial surgery and photodynamic therapy for early central lung cancer treatment**
S. Pirogov, L. Telegina, V. Sokolov, T. Karmakova, E. Filonenko, O. Pikin, A. Kaprin; Moscow, RU
- 12:30 - 12:30 **77P - The prognostic impact of the international association for the study of lung cancer (IASLC) definitions on completeness of surgical resection for non-small cell lung cancer (NSCLC)**
M. Gagliasso¹, C. Cartia², A. Maraschi², R. Rapanà², S. Sobrero², A. Sandri², G. Migliaretti², F. Ardissoni²; ¹Cuneo, IT, ²Orbassano, IT
- 12:30 - 12:30 **78P - Lung resection for cancer in patients with heart disease: Management and postoperative outcome**
F. Caushi, I. Skenduli, A. Hatibi, A. Mezini, S. Telo, S. Bala, E. Shima, A. Cani; Tirana, AL
- 12:30 - 12:30 **79P - Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer**
X. Chen, Y. Deng, Y. Shi; Fuzhou, CN
- 12:30 - 12:30 **80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)**
J.F. Cordoba Ortega¹, A. Salud², S. Morales², J. Veas², A. Rodriguez²; ¹Lleida, ES, ²Lerida, ES
- 12:30 - 12:30 **81P - Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer**
P. Rocha, M. Rodrigo, L. Moliner, M. Hardy-Werbin, D. Casadevall Aguilar, X. Durán, O. Arpí, S. Clavé, M. Salido, X. Riera, S. Menendez, Á. Taus, L. Pijuan, L. Comerma, E. Arriola Aperribay; Barcelona, ES
- 12:30 - 12:30 **82TiP - IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy**
S. Peters¹, A. Kim², B. Solomon³, D. Gandara⁴, R. Dziadziuszko⁵, A. Brunelli⁶, M. Garassino⁷, M. Reck⁸, L. Wang⁹, I. To⁹, S. Sun⁹, B. Gitlitz⁹, A. Sandler¹⁰, N. Rizvi¹¹; ¹Lausanne, CH, ²Los Angeles, CA/US, ³Melbourne, VIC/AU, ⁴Sacramento, CA/US, ⁵Gdańsk, PL, ⁶Leeds, GB, ⁷Milan, IT, ⁸Grosshansdorf, DE, ⁹South San Francisco, CA/US, ¹⁰South San Francisco, OR/US, ¹¹New York, NY/US
- 12:30 - 12:30 **87P - Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients**



A. Prelaj¹, S.E. Rebuzzi², P. Pizzutilo³, M. Bilancia³, M. Montrone³, F. Pesola³, V. Longo³, G. Del Bene³, V. Lapadula³, F. Cassano³, P. Petrillo³, D. Bafunno³, N. Varesano³, V. Lamorgese³, A. Mastranrdea³, D. Ricci³, A. Catino³, D. Galetta³; ¹Milan, IT, ²Genova, IT, ³Bari, IT

- 12:30 - 12:30 **89P - Treatment patterns and long-term survival for unresected stage III non-small cell lung cancer patients: A nationwide register study in Denmark**
A. Green¹, K. Olsen², M. Bliddal², H. Christensen¹, E. Jakobsen²; ¹Copenhagen, DK, ²Odense C, DK
- 12:30 - 12:30 **90P - Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database**
N. Girard¹, M. Pérol², G. Simon¹, C. Audigier Valette³, R. Gervais⁴, D. Debieuvre⁵, R. Schott⁶, X. Quantin⁷, B. Coudert⁸, H. Lena⁹, M. Carton¹, M. Robain¹, T. Filleron¹⁰, C. Chouaid¹¹; ¹Paris, FR, ²Lyon, CEDEX/FR, ³Toulon, CEDEX/FR, ⁴Caen, CEDEX 5/FR, ⁵Mulhouse, FR, ⁶Strasbourg, CEDEX/FR, ⁷Montpellier, CEDEX 5/FR, ⁸Dijon, Cedex/FR, ⁹Rennes, CEDEX/FR, ¹⁰Toulouse, CEDEX 3/FR, ¹¹Créteil, CEDEX 12/FR
- 12:30 - 12:30 **91P - Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns**
F. Hu¹, B. Zhang¹, C. Li¹, J. Xu¹, H. Wang¹, P. Gu¹, X. Zheng¹, W. Nie¹, Y. Shen¹, H. Zhang¹, P. Hu², X. Zhang¹; ¹Shanghai, CN, ²Zhenjiang, CN
- 12:30 - 12:30 **92P - A prospective study on the association of dose-volume histogram parameters with oesophagitis, radiation pneumonitis, radiation induced pulmonary fibrosis after receiving chemoradiation for NSCLC**
S. Bhowal, K. Chatterjee, J. Dey; Kolkata, IN
- 12:30 - 12:30 **93P - Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis**
J. Taugner¹, L. Käsmann², C. Eze², M. Dantes², O. Roengvoraphoj², K. Gennen², M. Karin², A. Tufman², C. Belka², F. Manapov²; ¹München, DE, ²Munich, DE
- 12:30 - 12:30 **94P - Challenges in the management of stage III non-small cell lung cancer (NSCLC) within multidisciplinary team (MDT): A lung cancer center experience**
K. Harbague, N. Mejri, H. El Benna, S. Labidi, N. Daoud, H. Boussen; Ariana, TN
- 12:30 - 12:30 **95P - The role of patient performance status and its changes before and after completion of multimodal treatment for inoperable stage III NSCLC**
L. Käsmann¹, J. Taugner², C. Eze¹, O. Roengvoraphoj¹, M. Dantes¹, K. Gennen¹, M. Karin¹, A. Tufman¹, C. Belka¹, F. Manapov¹; ¹Munich, DE, ²München, DE
- 12:30 - 12:30 **96P - Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC**



M. Hoffmann¹, J. Taugner¹, O. Roengvoraphoj², C. Eze², L. Käsmann², C. Belka², F. Manapov²; ¹München, DE, ²Munich, DE

- 12:30 - 12:30 **97P - Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy**
C. Eze¹, J. Taugner², L. Käsmann¹, O. Roengvoraphoj¹, N. Schmidt-Hegemann², M. Dantes¹, C. Belka¹, F. Manapov¹; ¹Munich, DE, ²München, DE
- 12:30 - 12:30 **98P - Implications for UK practice of the use of durvalumab in stage III NSCLC**
M.S. Iqbal¹, P. Atherton¹, C. Macgregor², A. Wieczorek³, J. Singer⁴, J. Walther⁵, F. Little⁶, S. Harden⁷, C. Peedell⁸, A. Cyriac⁹, S. Chowdhury⁴, M. Bayne¹⁰, K. Yip¹¹, A. Britten¹², C. Powell¹³, J. Brock¹², S. Datta¹⁴, T. Sevitt¹⁵, A. Mehta¹⁶, A. Greystoke¹⁷; ¹Newcastle Upon Tyne, GB, ²Inverness, GB, ³Cottingham, GB, ⁴Harlow, GB, ⁵Taunton, GB, ⁶Edinburgh, GB, ⁷Cambridge, GB, ⁸Middlesbrough, GB, ⁹Southend, GB, ¹⁰Poole, GB, ¹¹Ipswich, GB, ¹²Brighton, GB, ¹³Swansea, GB, ¹⁴Peterborough, GB, ¹⁵Maidstone, GB, ¹⁶Guildford, GB, ¹⁷Newcastle Upon Tyne, Tyne and Wear/GB
- 12:30 - 12:30 **99P - Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence**
F. Roitberg¹, M.F. Neffá¹, R. Bonadio¹, G. Harada¹, E. Mendoza², M. Mak¹, T. Takahashi¹, R. Martins¹, C. Mesquita¹, F. Santini¹, P. de Araújo¹, L. Lauricella¹, G. Prado¹, T. Takagaki¹, E. de Mello¹, F. Gabrielli¹, H. de Andrade Carvalho¹, R. Terra¹, G. de Castro Jr³; ¹Sao Paulo, BR, ²Quito, EC, ³São Paulo, BR
- 12:30 - 12:30 **100P - A new PET-CT score for locally-advanced inoperable NSCLC stage III patients treated with chemoradiotherapy**
O. Roengvoraphoj¹, C. Eze¹, J. Taugner², A. Gjika², A. Tufman¹, L. Käsmann¹, I. Hadi², E. Mille², C. Belka¹, F. Manapov¹; ¹Munich, DE, ²München, DE
- 12:30 - 12:30 **101TiP - PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy**
N. Girard¹, F. Mornex², D. Christoph³, R. Fietkau⁴, A. Filippi⁵, J. Field⁶, P. Garrido Lopez⁷, F. McDonald⁸, S. Peters⁹, A. Klein¹⁰, M. Licour¹¹, M. Garassino¹²; ¹Paris, FR, ²Pierre Bénite, FR, ³Essen, DE, ⁴Erlangen, DE, ⁵Pavia, IT, ⁶Liverpool, GB, ⁷Madrid, ES, ⁸London, GB, ⁹Lausanne, CH, ¹⁰Cambridge, GB, ¹¹Gaithersburg, US, ¹²Milan, IT
- 12:30 - 12:30 **121P - Risk of not receiving second-line therapy is high in EGFR mt&&**
J. Roeper¹, A. Lueers², M. Falk³, S. Schatz⁴, M. Tiemann⁴, C. Wesseler⁴, G.H. Wiest⁴, S. Sackmann⁵, D. Ukena⁵, L. Heukamp⁶, F. Griesinger²; ¹Berlin, DE, ²Oldenburg, DE, ³Hamburg, Hamburg/DE, ⁴Hamburg, DE, ⁵Bremen, DE, ⁶Köln, DE
- 12:30 - 12:30 **122P - Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts**



J.C. Yang¹, S. Ramalingam², C. Lee³, T. Kurata⁴, D. Kim⁵, T. John⁶, N. Nogami⁷, Y. Ohe⁸, Y. Rukazenzov⁹, M. Murphy¹⁰, P. Jänne¹¹; ¹Taipei City, TW, ²Atlanta, US, ³Kogarah, NSW/AU, ⁴Osaka, JP, ⁵Seoul, KR, ⁶Heidelberg, AU, ⁷Matsuyama, JP, ⁸Tokyo, JP, ⁹Macclesfield, Cheshire/GB, ¹⁰Cambridge, GB, ¹¹Boston, MA/US

- 12:30 - 12:30 **123P - Long term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-world study in China**
S. Wang, B. Han; Shanghai, CN
- 12:30 - 12:30 **124P - The effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation**
J. Li, D. Nickens, K. Wilner, W. Tan; San Diego, US
- 12:30 - 12:30 **125P - Elderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON**
W. Brückl¹, E. Laack², C. Kortsik³, H. Schaefer⁴, M. Reck⁵, A. Maerten⁶, C. Hoffmann⁶; ¹Nürnberg, DE, ²Berlin, DE, ³Mainz, DE, ⁴Völklingen, DE, ⁵Grosshansdorf, DE, ⁶Ingelheim Am Rhein, DE
- 12:30 - 12:30 **126P - Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire**
D. Sharma¹, F. Slevin¹, K. Clarke¹, K. Franks², M. Snee¹, P. Jain¹; ¹Leeds, GB, ²Leeds, Yorkshire/GB
- 12:30 - 12:30 **127P - Obesity has an impact on the efficacy of EGFR-TKI in NSCLC patients harbouring EGFR mutation: A real-world study**
Z. Ding, Y. Chen, Y. Hong, Y. Fu, L. Tong, Q. Li, P. Lin; Chengdu, CN
- 12:30 - 12:30 **128P - Frequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer**
M. Sow, H. El Yacoubi¹, B. Moukafih, S. Balde, G. Akimana, S. Elkhoyaali, H. Abahssain, H. Mrabti, I. Elghissassi, H. Errihani; Rabat, MA
- 12:30 - 12:30 **129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer**
Z. Lian, W. Du, J. Zhu, Y. Zeng, L. zeyi, J. Huang; Suzhou, CN
- 12:30 - 12:30 **130P - Relationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion**
J. Zhang, Z. Zhou, Y. Su, T. Yu; Nanning, CN
- 12:30 - 12:30 **131P - Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma**
C. Li, J. Guo, L. Zhao, F. Hu, W. Nie, H. Wang, X. Zheng, Y. Shen, P. Gu, Y. Zhang, X. Zhang; Shanghai, CN



- 12:30 - 12:30 **132P - New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer**
J. Fassunke¹, C. Heydt², S. Michels², B. Van Veggel³, F. Müller², M. Keul⁴, M.A. Dammert², A. Schmitt², E. Smit³, S. Kast⁴, J. Wolf¹, R. Buettner¹, M. Sos², D. Rauh⁴, S. Merkelbach-Bruse²; ¹Cologne, DE, ²Köln, DE, ³Amsterdam, NL, ⁴Dortmund, DE
- 12:30 - 12:30 **133P - A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant**
J. Qu, L. Liu, J. Heng, C. Zhou, Y. Xiong, W. Jiang, N. Yang; Changsha, CN
- 12:30 - 12:30 **134P - Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors**
S. Wagener-Rydzek¹, C. Heydt², J. Sueptitz², S. Michels², M. Falk³, C. Alidousty², J. Fassunke¹, M. Tiemann⁴, L. Heukamp², J. Wolf¹, R. Buettner¹, S. Merkelbach-Bruse²; ¹Cologne, DE, ²Köln, DE, ³Hamburg, Hamburg/DE, ⁴Hamburg, DE
- 12:30 - 12:30 **135P - EGFR & PD L1: An (im)perfect union**
U. Batra¹, M. Sharma², P. Jain², S. Bothra², S. Pasricha³; ¹New Delhi, Rohini/IN, ²New Delhi, IN, ³Delhi, IN
- 12:30 - 12:30 **136P - Correlation of molecular status and anatomic sites of metastases at diagnosis of EGFR positive non-small cell lung cancer (NSCLC): A single institution experience**
K. Krpina, B. Budimir, S. Kukulj, A. Marušić, M. Jakopović, M. Samaržija; Zagreb, HR
- 12:30 - 12:30 **137P - Detection and clinicopathologic features of ctDNA in T790M-positive advanced lung adenocarcinomas patients after failure of treatment with first- and second-generation EGFR-TKIs**
W. he, Z. Zhou, T. Yu, H. Zhao, Y. Su, P. Zeng; Nanning, CN
- 12:30 - 12:30 **138P - PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype**
Y. Zhang, T. Liu, Y. Zeng, J. Zhu, W. Du, L. zeyi, J. Huang; Suzhou, CN
- 12:30 - 12:30 **139P - Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States**
X. Pan¹, M. Lin², Y. Yin¹, P. Hou¹, P. Baumann¹, M. Jahanzeb³; ¹Cambridge, MA/US, ²Cambridge, US, ³Miami, FL/US
- 12:30 - 12:30 **140P - Brigatinib experience on the ALK project**
F. Gomes¹, N. Tokaca², K. Yip³, S. Ghosh², T. Newsom-Davis², A. Greystoke⁴, H. Mills², S. Ahmed⁵, A. Harle¹, G. Ayre⁶, R. Shah⁷, S. Popat², F. Blackhall¹, Y. Summers¹; ¹Manchester, GB, ²London, GB, ³Ipswich, GB, ⁴Newcastle Upon Tyne, Tyne and Wear/GB, ⁵Leicester, GB, ⁶Bristol, GB, ⁷Maidstone, Kent/GB



- 12:30 - 12:30 **141P - Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)**
L. Angelats¹, M.R. Garcia Campelo², R. Bernabe Caro³, E. Arriola Aperrribay⁴, V. Calvo de Juan⁵, A. Barba Joaquín⁴, N. Vinolas Segarra⁴, M. Gil Moreno⁶, L. Vilà Martinez⁷, O.J. Juan Vidal⁸, N. Vilariño Quintela⁴, M. Cobo⁹, E. Sais¹⁰, M. Domine Gomez¹¹, N. Fernandez Nuñez¹², J. Coves Sarto¹³, R. Marse Fabregat¹⁴, A.M. Esteve Gomez¹, D. Rodríguez-Abreu¹⁵, E. Carcereny Costa¹⁶; ¹Badalona, ES, ²Coruna, ES, ³Sevilla, ES, ⁴Barcelona, ES, ⁵Majadahonda, Madrid/ES, ⁶Barcelona, Barcelona/ES, ⁷Sabadell, Barcelona/ES, ⁸Valencia, ES, ⁹Malaga, ES, ¹⁰Girona, ES, ¹¹Madrid, ES, ¹²Lugo, ES, ¹³Palma De Mallorca, Islas Baleares/ES, ¹⁴Palma De Mallorca, ES, ¹⁵Las Palmas, ES, ¹⁶Badalona, Barcelona/ES
- 12:30 - 12:30 **142P - Clinical management of advanced lung adenocarcinoma with ALK rearrangement: Real-world treatment outcomes and long-term survival**
B. Zhang, S. Wang, J. Xu, Y. Zhang, X. Zhang, J. Qian, J. Lu, R. Qiao, W. Nie, L. Zhang, Y. Zhao, M. Hu, W. Zhang, B. Han; Shanghai, CN
- 12:30 - 12:30 **143P - Role of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study**
Y. Zhao, B. Zhang, Y. Zhang, S. Wang, J. Qian, B. Han; Shanghai, CN
- 12:30 - 12:30 **144P - Clinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs**
A. Passaro, A. Prelaj, G. Spitaleri, E. Del Signore, G. Rossi, E. Guerini-Rocco, M. Barberis, C. Catania, F. de Marinis; Milan, IT
- 12:30 - 12:30 **145P - Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients**
C.Y.X. Kho, D. Lim, D.S.W. Tan, W.L. Tan, T. Rajasekaran, A. Jain, C.K. Toh, M. Ang, E.H. Tan, Q.S. Ng; Singapore, SG
- 12:30 - 12:30 **146P - Clinical significance of ROS1 deletions detected by FISH and response to crizotinib**
F. Dall'Olio, G. Lamberti, E. Capizzi, E. Gruppioni, F. Sperandi, A. Altimari, F. Giunchi, M. Fiorentino, A. Ardizzoni; Bologna, IT
- 12:30 - 12:30 **147P - Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 mutations in non-small cell lung cancer (NSCLC)**
M. Scheffler¹, R. Frank², M. Ihle², D. Abdulla¹, S. Koleczko², L. Nogova², A. Holzem², T. Chanra¹, R. Riedel¹, S. Michels², R. Fischer², A. Kron¹, S. Merkelbach-Bruse², R. Buettner², J. Wolf¹; ¹Cologne, DE, ²Köln, DE
- 12:30 - 12:30 **148P - KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC**



M. Cinausero¹, N. Laprovitera², G. De Maglio¹, L. Gerratana¹, M. Riefolo², M. Macerelli¹, M. Fiorentino², E. Porcellini², V. Buoro¹, F. Gelsomino², A. Squadrilli³, G. Fasola¹, M. Tiseo³, M. Ferracin², A. Ardizzoni²; ¹Udine, IT, ²Bologna, IT, ³Parma, IT

- 12:30 - 12:30 **149P - Efficacy of tyrosine kinase inhibitors (TKIs) in advanced lung adenosquamous carcinoma**
M. Hu, B. Zhang, S. Wang, Y. Shen, J. Qian, Y. Zhao, B. Han; Shanghai, CN
- 12:30 - 12:30 **150P - Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy**
G. Galli¹, C. Proto², D. Signorelli¹, M. Imbimbo¹, R. Ferrara², A. Prelaj², A. De Toma², G. Randon², B. Trevisan², M. Ganzinelli², N. Zilembo², M. Garassino¹, G. Lo Russo²; ¹Milan, IT, ²Milano, IT
- 12:30 - 12:30 **151P - Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study**
H. Horinouchi¹, N. Nogami², H. Saka³, M. Nishio¹, T. Tokito⁴, T. Takahashi⁵, K. Kasahara⁶, Y. Hattori⁷, E. Ichihara⁸, N. Adachi¹, T. Sawada¹, T. Shimamoto¹, K. Noguchi¹, M..C. Pietanza⁹, T. Kurata¹⁰; ¹Tokyo, JP, ²Matsuyama, JP, ³Nagoya, JP, ⁴Kurume, JP, ⁵Shizuoka, Shizuoka/Jp, ⁶Kanazawa, JP, ⁷Akashi, JP, ⁸Okayama, JP, ⁹Kenilworth, NJ/US, ¹⁰Osaka, JP
- 12:30 - 12:30 **152P - Correlation among different KRAS alterations, genetic co-mutations and PD-L1 expression in patients treated with immunotherapy in metastatic NSCLC**
L. Gianoncelli¹, G. Spitaleri¹, A. Passaro¹, C. Fumagalli¹, P. Trillo Aliaga¹, E. Del Signore², V. Stati¹, E. Ferraro³, E. Guerini-Rocco¹, C. Catania¹, M. Barberis¹, F. de Marinis¹; ¹Milan, IT, ²Roma, IT, ³Rozzano, (MI)/IT
- 12:30 - 12:30 **153P - Chemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis**
A. Addeo¹, G. Banna², G. Metro³, M. Di Maio⁴; ¹Geneva, CH, ²Catania, IT, ³Perugia, (PG)/IT, ⁴Torino, IT
- 12:30 - 12:30 **154P - Renal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy**
D. Dumoulin¹, S. Visser², R. Cornelissen³, J. Aerts⁴; ¹Barendrecht, NL, ²Breda, NL, ³Rotterdam, NL, ⁴Rotterdam, Noord Brabant/NL
- 12:30 - 12:30 **155P - Association of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC)**
C. Saavedra Serrano, A. Barquín García, E. Corral de la Fuente, J.J. Serrano Domingo, V. Albarrán Artahona, R. Martín Huertas, A. Gómez Rueda, M.E. Olmedo García; Madrid, ES



- 12:30 - 12:30 **156P - Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients**
A. Prelaj¹, S.E. Rebutzi², P. Pizzutilo³, M. Bilancia³, M. Montrone³, F. Pesola³, V. Longo³, G. Del Bene³, V. Lapadula³, F. Cassano³, P. Petrillo³, D. Bafunno³, N. Varesano³, V. Lamorgese³, A. Mastranrdea³, D. Ricci³, A. Catino³, D. Galetta³; ¹Milan, IT, ²Genova, IT, ³Bari, IT
- 12:30 - 12:30 **157P - Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies**
A. Schett¹, S. Rothschild¹, L. Mauti², S. Schmid², C. Appenzeller², A. Curioni-Fontecedro³, M. Frueh², M. Joerger²; ¹Basel, CH, ²St. Gallen, CH, ³Zurich, CH
- 12:30 - 12:30 **158P - Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse**
A. Pavan¹, L. Calvetti², A. Dal Maso¹, I. Attili¹, G. Pasello¹, G. Aprile³, V. Guarneri¹, P. Conte¹, L. Bonanno¹; ¹Padova, IT, ²Verona, IT, ³Vicenza, IT
- 12:30 - 12:30 **159P - Initial serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC**
D. Lang, A. Horner, E. Brehm, K. Akbari, B. Hergan, K. Langer, C. Asel, M. Scala, B. Kaiser, B. Lamprecht; Linz, AT
- 12:30 - 12:30 **160P - EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy**
A. Prelaj¹, G. Lo Russo², D. Signorelli¹, R. Ferrara², M. Imbimbo¹, G. Galli¹, A. De Toma², G. Randon², M. Brambilla¹, B. Trevisan², M. Ganzinelli², N. Zilembo², F. De Braud¹, M. Garassino¹, C. Proto²; ¹Milan, IT, ²Milano, IT
- 12:30 - 12:30 **161P - Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer**
P. Jermann¹, I. Alborelli¹, K. Leonards¹, S. Rothschild¹, L. Leuenberger¹, S. Savic Prince¹, K. Mertz², S. Poechtrager², A. Zippelius¹, L. Quagliata¹, L. Bubendorf¹; ¹Basel, CH, ²Liestal, CH
- 12:30 - 12:30 **162P - Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCCLC)**
V. Di Noia¹, E. D'Argento¹, E. Vita¹, M. Ferrara¹, P. Damiano¹, M. Ribelli¹, A. Cannella¹, A. Virtuoso¹, G. Tortora¹, E. Bria²; ¹Rome, IT, ²Roma, IT
- 12:30 - 12:30 **163P - Immuno-oncological treatment and tumor load in non-small cell lung cancer (NSCLC): Case-control analysis of overall survival (OS) in routine clinical practice**
M. Faehling, B. Schwenk, M. Kopp, S. Fallscheer, S. Kramberg, R. Eckert; Esslingen, DE



- 12:30 - 12:30 **164P - PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC**
Y. Qin, L. Jiang, Y. Li, L. Ren, Y. Wang, Y. Gong, F. Peng, J. Zhu, Z. Ding, Y. Liu, M. Yu, Y. Lu, M. Huang; Chengdu, CN
- 12:30 - 12:30 **165P - Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis**
T. Landre¹, G. Des Guetz², A. Vergnenegre³, C. Chouaid⁴; ¹Sevrans, FR, ²Bobigny, CEDEX/FR, ³Limoges, CEDEX/FR, ⁴Créteil, CEDEX 12/FR
- 12:30 - 12:30 **166P - Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a prospective, observational, single institution study**
K. Rounis¹, C. Papadaki¹, D. Makrakis¹, A. Monastirioti¹, L. Vamvakas², K. Kalbakis¹, D. Mavroudis¹, S. Aggelaki¹; ¹Heraklion, GR, ²Heraklion, Crete/GR
- 12:30 - 12:30 **167P - Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer**
B. Rapoport¹, D. Vorobiof², L. Langenhoven³, J. Hall⁴, R. Van Eeden¹, T. Smit¹, S.W. Chan⁵, M. Botha⁶, J. Raats³, M. De Necker⁷, H. Duvenhage⁸; ¹Sandton, ZA, ²Bnei Atarot, Gauteng/IL, ³Cape Town, ZA, ⁴Cape Town, Western Cape/ZA, ⁵Sandton, Gauteng/ZA, ⁶George, Western Cape/ZA, ⁷Pretoria, ZA, ⁸Woodmead, ZA
- 12:30 - 12:30 **168P - Dynamic changes of platelet-to-lymphocyte ratio predict efficacy of PD-1/PD-L1 inhibitors in NSCLC**
F. Zhou, A. Xiong, C. Zhou; Shanghai, CN
- 12:30 - 12:30 **169P_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)**
E. Corral de la Fuente, A. Barquín García, C. Saavedra Serrano, M.E. Olmedo García, R. Martín Huertas, J.J. Serrano Domingo, V. Albarrán Artahona, A. Gómez Rueda; Madrid, ES
- 12:30 - 12:30 **170P - Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade**
W. Nie¹, M. Xu¹, L. Gan¹, Y. Zhang², B. Han¹; ¹Shanghai, CN, ²Chongqing, CN
- 12:30 - 12:30 **171P - Previous exposure to bevacizumab indicated inferior benefits from PD-1/PD-L1 inhibitors in nonsquamous NSCLC**
F. Zhou, Y. Pan, C. Zhou; Shanghai, CN
- 12:30 - 12:30 **172P - A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer**



B. Han¹, K. Li², T. Chu¹, M. Bi³, H. Zhang⁴, Y. Yu⁵, J. Shi⁶, X. Zhang⁷, Z. Chen⁸, C. Han⁹, T. Bai⁹; ¹Shanghai, CN, ²Tianjin, CN, ³Bengbu, CN, ⁴Xi'an, CN, ⁵Harbin, CN, ⁶Linyi, CN, ⁷Qingdao, CN, ⁸Hefei, CN, ⁹Jinan, CN

- 12:30 - 12:30 **173P - Stereotactic radiotherapy concurrent to immune or targeted therapy for oligometastatic NSCLC: Clinical scenarios affecting survival**
S. Kroeze¹, C. Fritz¹, D. Kaul², O. Blanck³, K. Kahl⁴, F. Roeder⁵, S. Siva⁶, J. Verhoeff⁷, A. Grosu⁸, M. Schymalla⁹, M. Glatzer¹⁰, M. Szuets¹¹, M. Geier¹², G. Skazikis¹³, I. Sackerer¹⁴, F. Lohaus¹⁵, F. Eckert¹⁶, M. Guckenberger¹⁷; ¹Zurich, CH, ²Berlin, DE, ³Gustow, DE, ⁴Augsburg, DE, ⁵München, DE, ⁶Melbourne, AU, ⁷Utrecht, NL, ⁸Freiburg, DE, ⁹Marburg, DE, ¹⁰St. Gallen, CH, ¹¹Rostock, DE, ¹²Linz, AT, ¹³Villingen-Schwenningen, DE, ¹⁴Freising, DE, ¹⁵Dresden, DE, ¹⁶Tübingen, DE, ¹⁷Zürich, CH
- 12:30 - 12:30 **174P - NSCLC stages IIa-IIIc: Tumor related IGRT yields better local control than kV-guidance to anatomic structures**
F. Zehentmayr¹, J. Karner¹, K. Wurstbauer², R. Wass³, G. Fastner¹, L. Rettenbacher¹, M. Studnicka¹, C. Pirich¹, P. Kopp¹, F. Sedlmayer¹; ¹Salzburg, AT, ²Feldkirch, AT, ³Linz, AT
- 12:30 - 12:30 **175P - Permanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non-small cell lung cancer (NSCLC)**
M. Martinez Kareaga¹, N. Urbieta-Macazaga², C. Sanchez-Vieco³, L. Tomás-López³, I. Intxaurbe-Etxebarria³, B. Mareque³, N. Torregoa³, A. Narro³, L. Puntí³, I. Guillen³; ¹Vitoria-Gasteiz, ES, ²San Sebastian, ES, ³Vitoria, ES
- 12:30 - 12:30 **176P - Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy**
M. Altini¹, I. Massa¹, W. Balzi¹, N. Gentili¹, F. Foca¹, V. Danesi¹, S. Manunta¹, M. Burgio¹, P. Cravero¹, F. Ejzykowicz², S. Chandwani², A. Delmonte¹; ¹Meldola, IT, ²Rahway, NJ/US
- 12:30 - 12:30 **177P - Real-world experience of ALK positive NSCLC from India**
M. Malhotra, V. Noronha, A. Joshi, V. Patil, S. Wadhwa, K. Prabhash; Mumbai, IN
- 12:30 - 12:30 **178P - Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients**
D. Abdulla¹, M. Ruge¹, M. Scheffler¹, L. Nogova², S. Koleczko², T. Persigehl¹, S. Grau¹, A. Drzezga¹, C. Kobe¹, R. Buettner², N. Galldiks¹, J. Wolf¹; ¹Cologne, DE, ²Köln, DE
- 12:30 - 12:30 **179P - Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice**
M. Frueh¹, O. Rahma², R. Pachynski³, J. Mazieres⁴, J. Goldschmidt Jr.⁵, T. Ton⁶, S. Mhatre⁶, C. Chuo⁶, J. Martinalbo⁷, J. Davies⁸, R. Juergens⁹; ¹St. Gallen, CH, ²Boston, MA/US, ³St. Louis, MO/US, ⁴Toulouse, FR, ⁵Blacksburg, VA/US, ⁶South San Francisco, CA/US, ⁷Basel, CH, ⁸Welwyn Garden City, GB, ⁹Hamilton, ON/CA



- 12:30 - 12:30 **180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer**
J. Spicer¹, M. Provencio², P. Garrido Lopez², J. Bosch-Barrera³, F.J. de Castro Carpeño², E. Felip⁴, J. Trigo⁵, S. Viteri⁴, E. Coart⁶, E. Schmidt⁷, A. Christiansen⁸, M. Zocca⁸, M. Andersen⁸, E. Ehrnrooth⁸, L. Paz-Ares²; ¹London, GB, ²Madrid, ES, ³Girona, ES, ⁴Barcelona, ES, ⁵Malaga, ES, ⁶Ottignies, BE, ⁷Kenilworth, NJ/US, ⁸Copenhagen, DK
- 12:30 - 12:30 **181TiP - Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study**
M. Shimokawa¹, K. Nosaki¹, T. Seto², K. Ohashi³, M. Morise⁴, Y. Fujiwara⁵, J. Sakakibara⁶, H. Murakami⁷, S. Yano⁸, M. Satouchi⁹, S. Matsumoto¹⁰, K. Goto¹⁰, K. Yoh¹⁰; ¹Fukuoka, JP, ²Fukuoka, Fukuoka/JP, ³Okayama, JP, ⁴Nagoya, JP, ⁵Tokyo, JP, ⁶Sapporo, JP, ⁷Shizuoka, JP, ⁸Kanazawa, JP, ⁹Akashi, JP, ¹⁰Kashiwa, Chiba/JP
- 12:30 - 12:30 **182TiP - A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study**
P. Paik¹, A. Cortot², E. Felip³, H. Sakai⁴, J. Mazieres⁵, L. Horn⁶, F. Griesinger⁷, R. Bruns⁸, J. Scheele⁸, J. Straub⁸, R. Veillon⁹; ¹New York City, NY/US, ²Lille, FR, ³Barcelona, ES, ⁴Saitama, JP, ⁵Toulouse, FR, ⁶Nashville, TN/US, ⁷Oldenburg, DE, ⁸Darmstadt, DE, ⁹Pessac, FR
- 12:30 - 12:30 **183TiP - A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer**
D. Planchard¹, B. Li², H. Murakami³, R. Shiga⁴, C. Lee⁵, K. Wang⁵, P. Jänne⁶; ¹Villejuif, FR, ²New York, NY/US, ³Shizuoka, JP, ⁴Tokyo, JP, ⁵Basking Ridge, NJ/US, ⁶Boston, MA/US
- 12:30 - 12:30 **184TiP - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC**
L. Nogova¹, F. Malchers¹, A. Hillmer², S. Merkelbach-Bruse¹, A. Pinto¹, C. Woempner¹, R. Riedel³, M. Scheffler³, S. Michels¹, P. De Porre⁴, A. Santiago-Walker⁵, R. Fischer¹, D. Abdulla³, R. Thomas¹, R. Buettner¹, J. Wolf³; ¹Köln, DE, ²Mainz, DE, ³Cologne, DE, ⁴Beerse, BE, ⁵Spring House, US
- 12:30 - 12:30 **185TiP - RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)**
L. Paz-Ares¹, S. Senan², D. Planchard³, L. Wang⁴, A. Cheong⁵, R. Slepets⁵, M. Nguyen⁵, E. Vokes⁶; ¹Madrid, ES, ²Amsterdam, NL, ³Villejuif, FR, ⁴Shenzhen, CN, ⁵Summit, NJ/US, ⁶Chicago, IL/US
- 12:30 - 12:30 **186TiP - An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial**



F. Gelsomino¹, M. Tiseo², L. Boni³, L. Cavanna⁴, A. Camerini⁵, R. Chiari⁶, C. Verusio⁷, M. Tognetto¹, A. Ardizzoni¹; ¹Bologna, IT, ²Parma, IT, ³Firenze, IT, ⁴Piacenza, IT, ⁵Lido Di Camaiore, (LU)/IT, ⁶Perugia, IT, ⁷Saronno, (VA)/IT

- 12:30 - 12:30 **187TiP - Tumor treating fields concurrent with standard of care therapy for stage IV NSCLC following platinum failure: Phase III LUNAR study**
U. Weinberg¹, O. Farber², M. Giladi², Z. Bomzon², E. Kirson²; ¹Luzern, CH, ²Haifa, IL
- 12:30 - 12:30 **188TiP - Metformin +- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial**
G. Galli¹, D. Signorelli¹, C. Vernieri¹, M. Ganzinelli², M. Moro¹, A. Fabbri¹, E. Tamborini², M. Marabese¹, E. Caiola¹, M. Brogginini¹, L. Hollander¹, R. Gallucci¹, C. Gavazzi¹, A.M. Rizzo², P. Corsetto², G. Pruneri¹, F. de Braud¹, G. Sozzi¹, V. Torri³, M. Garassino¹; ¹Milan, IT, ²Milano, IT, ³No City Provided, NA
- 12:30 - 12:30 **190P - ERGR-TKIs combined with chemotherapy delays intracranial progression in EGFR-mutant lung adenocarcinoma patients**
C. Li, B. Zhang, J. Guo, F. Hu, W. Nie, X. Zheng, Y. Lou, Y. Shen, X. Zhang; Shanghai, CN
- 12:30 - 12:30 **191P - Assessment of toxicity and clinical outcomes with SBRT in lung metastases: A single institute experience**
V. Pareek, Mumbai, IN
- 12:30 - 12:30 **192P - Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis**
A. Raniszewska, E. Rutkowska, R. Sokolowski, J. Domagala-Kulawik; Warsaw, PL
- 12:30 - 12:30 **193P - Management of cN2 NSCLC patients treated with radical radiotherapy: Relapse with or without brain metastases**
F. McKay, S. Ansel, C. Lowrie, P. McLoone, N. Mohammed; Glasgow, GB
- 12:30 - 12:30 **195TiP - Phase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)**
M. Mehta¹, V. Gondi², M. Ahluwalia³, P. Brown⁴; ¹Chicago, IL/US, ²Warrenville, IL/US, ³Cleveland, OH/US, ⁴Rochester, MN/US
- 12:30 - 12:30 **197P - Effect of surgical treatment on the survival in patients with malignant pleural mesothelioma**
R. Baez-Saldana¹, M.T. Marmolejo-Torres², M. Iñiguez-García², J.A. Berrios Mejía², U. Rumbo-Nava², O. Arrieta-Rodríguez²; ¹Ciudad De México, MX, ²Mexico City, MX
- 12:30 - 12:30 **198P - Efficacy of 150 kHz tumor treating fields (TTFields) and cisplatin or pemetrexed for the treatment of mesothelioma cells in vitro**



U. Weinberg¹, M. Munster², K. Gotlib², R. Schneiderman², Y. Porat², T. Voloshin Sela², S. Davidi², A. Shteingauz², N. Kaynan², E. Zeevi², M. Giladi², E. Kirson², A. Kinzel³, Y. Palti²; ¹Luzern, CH, ²Haifa, IL, ³München, DE

- 12:30 - 12:30 **199P - Safety meta-analysis of clinical trials delivering TTFields to the upper torso**
G.L. Ceresoli¹, M. Pless²; ¹Bergamo, IT, ²Winterthur, CH
- 12:30 - 12:30 **200P - Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center**
K. Leventakos¹, J. Helgeson¹, A. Mansfield¹, E. Deering¹, A. Schwecke¹, A. Adjei¹, J. Molina¹, C. Hocum¹, T. Halfdanarson¹, R. Marks¹, K. Parikh¹, K. Pomerleau¹, S. Coverdill², M. Rammage², T. Haddad¹; ¹Rochester, MN/US, ²Cambridge, MA/US
- 12:30 - 12:30 **201P - Psychosocial and financial impact on family of lung cancer patients: A cancer research center experience**
S. GODARA, S. Beniwal; Bikaner, IN
- 12:30 - 12:30 **202P - Information for lung cancer patients and their caregivers: A systematic analysis of the online landscape**
P. Naish¹, E. Purdy²; ¹Cambridge, GB, ²London, GB
- 12:30 - 12:30 **203P - Retrospective study about lung carcinoid: Our experience in a Spanish hospital**
D. Sanchez Cabrero, P. Cruz, J. de Castro, O. Higuera, A. Pertejo, I. Esteban, L. Gutierrez, J. Villamayor, L. Ostios, D. Viñal, J. Miranda; Madrid, ES
- 12:30 - 12:30 **204P - Diagnostic value of concomitant use of radial probe endobronchial ultrasound with guide sheath and transbronchial biopsy in lung cancer**
S.C. Lee¹, S. Kwak², M.S. Park², Y.S. Kim², J. Chang², S.H. Lee², C.H. Han¹, S.M. Lee¹, C.J. Kim¹; ¹Goyang, KR, ²Seoul, KR
- 12:30 - 12:30 **205P - Non-small cell lung cancer in the elderly: A retrospective study comparing first-line treatment with single-agent vs combination chemotherapy vs tyrosine kinase inhibitor**
É. Cipriano, A. Tavares, A. Soares, F. Estevinho, C. Sottomayor; Matosinhos, PT
- 12:30 - 12:30 **206P - Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center**
I. TSIROUPROU, V. Tsartsianidou, S. Papaemmanouil, N. Pastelli, S. Lampaki, E. Eleftheriadou, K. Domvri, T. Kontakiotis, D. Spyrtatos; Thessaloniki (exohi), GR
- 12:30 - 12:30 **207P - Primary mucinous carcinomas of the lung: Clinical characteristics and treatment outcomes**
A. Thottian¹, G. Babu², L. Dasappa², L. Jacob², S. Babu², K.N. Lokesh³, A. Rudresha³, L. Rajeev², S. Saldanha², G. Gv²; ¹Delhi, Delhi/IN, ²Bangalore, IN, ³Bangalore, Karnatka/IN



- 12:30 - 12:30 **208P - Sarcopenia as prognostic factor in lung cancer patients: A systematic review and meta-analysis**
J. Büntzel¹, J. Heinz¹, C. Röver¹, A. Bleckmann¹, C. Bauer², A. Emmert¹; ¹Göttingen, DE, ²Fulda, DE
- 12:30 - 12:30 **209P - Feasibility and utility of transbronchial cryobiopsy in primary lung cancer: Prospective, single arm study**
K. Kirit¹, H. Udagawa², S. Matsumoto¹, K. Yoh¹, S. Niho¹, K. Goto¹; ¹Kashiwa, Chiba/JP, ²Kashiwa, JP
- 12:30 - 12:30 **210TiP - Evaluation of safety and efficacy of minocycline combined with tyrosine kinase inhibitors in patients of EGFR mutated metastatic lung cancer**
A. Thottian¹, G. Babu², L. Dasappa², L. Jacob², S. Babu², K.N. Lokesh³, A. Rudresha³, S. Saldanha², G. Gv², R. Lk²; ¹Delhi, Delhi/IN, ²Bangalore, IN, ³Bangalore, Karnatka/IN
- 13:00 - 14:00 MSD - Industry Satellite Symposium Room A**
 Moderation: N. Leighl, Toronto, CA
- 13:00 - 13:05 **Welcome and introduction**
N. Leighl, Toronto, CA
- 13:05 - 13:20 **IO combinations in first-line NSCLC**
D. Rodríguez-Abreu, Las Palmas, ES
- 13:20 - 13:35 **Role of monotherapy in first-line NSCLC**
N. Leighl, Toronto, CA
- 13:35 - 13:50 **Patient profiles/cases**
S. Liu, Washington, DC/US
- 13:50 - 14:00 **Q&A and Closing Remarks**
N. Leighl, Toronto, CA
- 14:10 - 14:40 Microbiome in cancer immunotherapy Room B**
 Moderation: P. Garrido Lopez, Madrid, ES
- 14:10 - 14:10 **Session DOI**
- 14:10 - 14:40 **Microbiome in cancer immunotherapy**
L. Zitvogel, Villejuif, CEDEX/FR



14:45 - 16:15 Management of side effects and toxicities Room A
Moderation: D. Isla¹, B. Besse²; ¹Zaragoza, ES, ²Villejuif, CEDEX/FR

14:45 - 14:45 **Session DOI**

14:45 - 15:00 **Management of I-O toxicities: An introduction**
D. Isla, Zaragoza, ES

15:00 - 15:15 **Management of pulmonary toxicities: Clinical case**
M. Garassino, Milan, IT

15:15 - 15:30 **Management of endocrine toxicities: Clinical case**
J. Haanen, Amsterdam, NL

15:30 - 15:45 **Management of GI toxicities: Clinical case**
M. Sebastian, Frankfurt Am Main, DE

15:45 - 16:15 **Q&A**

14:45 - 16:15 SCLC: What are the challenges and how can we face them? Room C
Moderation: F.H. Blackhall¹, C. Le Pechoux²; ¹Manchester, GB, ²Villejuif, CEDEX/FR

14:45 - 14:45 **Session DOI**

14:45 - 15:05 **The pathologist's point of view**
F. Lopez-Rios, Madrid, ES

15:05 - 15:25 **The medical oncologist's point of view**
F. Blackhall, Manchester, GB

15:25 - 15:45 **The radiation oncologist's point of view**
C. Le Pechoux, Villejuif, CEDEX/FR

15:45 - 16:05 **The surgeon's point of view**
M. Casiraghi, Milan, IT

16:05 - 16:15 **Q&A**



- | | | |
|--|---|---------------|
| 14:45 - 16:15 | ESMO-IASLC Best Abstracts | Room B |
| Moderation: P. Garrido Lopez ¹ , J. Wolf ² ; ¹ Madrid, ES, ² Cologne, DE | | |
| 14:45 - 14:45 | Session DOI | |
| 14:45 - 15:00 | <p>LBA1_PR - Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study</p> <p><u>T. Owonikoko</u>¹, H.R. Kim², R. Govindan³, N. Ready⁴, M. Reck⁵, S. Peters⁶, S. Dakhil⁷, A. Navarro⁸, J. Rodriguez-Cid⁹, M. Schenker¹⁰, J. Lee², V. Gutierrez¹¹, I. Percent¹², D. Morgensztern³, J. Fairchild¹³, C. Baudelet¹³, K. Park²; ¹Atlanta, GA/US, ²Seoul, KR, ³St. Louis, MO/US, ⁴Durham, NC/US, ⁵Grosshansdorf, DE, ⁶Lausanne, CH, ⁷Wichita, KS/US, ⁸Barcelona, ES, ⁹Mexico City, MX, ¹⁰Craiova, Dolj/RO, ¹¹Malaga, ES, ¹²Punta Gorda, FL/US, ¹³Princeton, NJ/US</p> | |
| 15:00 - 15:15 | <p>LBA3 - Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC</p> <p><u>B.C. Cho</u>¹, N. Reinmuth², K.H. Lee³, M. Ahn¹, A. Luft⁴, M. Van den Heuvel⁵, M. Cobo Dols⁶, A. Smolin⁷, D. Vicente⁸, V. Moiseyenko⁴, S. Antonia⁹, S. Le Moulec¹⁰, G. Robinet¹¹, R. Natale¹², E. Garon¹³, K. Nakagawa¹⁴, F. Liu¹⁵, P. Thiyagarajah¹⁶, S. Peters¹⁷, N. Rizvi¹⁸; ¹Seoul, KR, ²Gauting, DE, ³Cheongju, KR, ⁴Saint-Petersburg, RU, ⁵Amsterdam, NL, ⁶Málaga, ES, ⁷Moscow, RU, ⁸Seville, ES, ⁹Tampa, FL/US, ¹⁰Paris, CEDEX 5/FR, ¹¹Brest, Cedex 2/FR, ¹²Los Angeles, US, ¹³Santa Monica, CA/US, ¹⁴Osaka, JP, ¹⁵Gaithersburg, US, ¹⁶Cambridge, GB, ¹⁷Lausanne, CH, ¹⁸New York, US</p> | |
| 15:15 - 15:30 | <p>Invited Discussant LBA1_PR and LBA3</p> <p><u>L. Paz-Ares</u>, Madrid, ES</p> | |
| 15:30 - 15:45 | <p>1020 - Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC</p> <p><u>T.S.K. Mok</u>¹, Y. Wu², I. Kudaba³, D. Kowalski⁴, B.C. Cho⁵, H. Turna⁶, G. de Castro Jr⁷, V. Srimuninnimit⁸, K. Laktionov⁹, I. Bondarenko¹⁰, K. Kubota¹¹, C. Caglevic¹², B. Karaszewska¹³, T. Dang¹⁴, L. Yin¹⁴, J. Penrod¹⁴, G. Lopes¹⁵; ¹Shatin, HK, ²Guangdong, CN, ³Riga, LV, ⁴Warsaw, PL, ⁵Seoul, KR, ⁶Istanbul, TR, ⁷São Paulo, BR, ⁸Bangkok, TH, ⁹Moscow, RU, ¹⁰Dnipro, UA, ¹¹Tokyo, JP, ¹²Santiago, CL, ¹³Konin, PL, ¹⁴Kenilworth, NJ/US, ¹⁵Miami, FL/US</p> | |
| 15:45 - 16:00 | <p>1030_PR - Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1-positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042</p> | |



K. Nosaki¹, Y. Hosomi², H. Saka³, P. Baas⁴, G. de Castro Jr⁵, M. Reck⁶, Y. Wu⁷, J. Brahmer⁸, E. Felip⁹, T. Sawada², K. Noguchi², S.R. Han², B. Piperdi¹⁰, D. Kush¹⁰, G. Lopes¹¹; ¹Fukuoka, JP, ²Tokyo, JP, ³Nagoya, JP, ⁴Amsterdam, NL, ⁵São Paulo, BR, ⁶Grosshansdorf, DE, ⁷Guangdong, CN, ⁸Baltimore, US, ⁹Barcelona, ES, ¹⁰Kenilworth, NJ/US, ¹¹Miami, FL/US

16:00 - 16:15 **Invited Discussant 1020 and 1030_PR**

S. Popat, London, GB

16:15 - 16:45 Coffee break

Hall 1

16:40 - 17:40 Mini Oral session II

Room C

Moderation: F. Cappuzzo¹, D. Isla², S. Peters³; ¹Ravenna, IT, ²Zaragoza, ES, ³Lausanne, CH

16:40 - 16:40 **Session DOI**

16:40 - 16:45 **10 - Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma**

A. Januszewski, Y.Z. Zhang, W. Chang, U. Laggner, A. Bowman, T. Adefila-Ideozu, I. Vivanco, M. Moffatt, W. Cookson, N. Gupta, A.G. Nicholson, A. Bowcock, S. Popat; London, GB

16:45 - 16:50 **850 - Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC)**

D. Planchard¹, M. Garassino², L. Paz-Ares³, C. Faivre-Finn⁴, A. Spira⁵, Y. Gu⁶, C. Wadsworth⁷, J. Whiteley⁸, M. Scott⁸, A. Boothman⁹, M. Ratcliffe⁷, J. Walker¹⁰, P. Dennis⁶, S. Antonia¹¹; ¹Villejuif, FR, ²Milan, IT, ³Madrid, ES, ⁴Manchester, GB, ⁵Fairfax, US, ⁶Gaithersburg, MD/US, ⁷Macclesfield, GB, ⁸Cambridge, GB, ⁹Melbourn, GB, ¹⁰Zoetermeer, NL, ¹¹Tampa, FL/US

16:50 - 16:55 **1160 - Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study**

M. Pérol¹, A. Dixmier², F. Barlesi³, D. Debieuvre⁴, C. Raspaud⁵, J.B. Auliac⁶, N. Benoit⁷, P. Bombaron⁸, D. Moro-Sibilot⁹, B. Asselain¹⁰, F. Cotté¹¹, P. Lamoureux¹², N. Karam¹¹, N. Ozan¹¹, C. Calvet¹¹, B. Bryan¹³, V. Allan¹³, C. Audigier Valette¹⁴; ¹Lyon, CEDEX/FR, ²Orleans, FR, ³Marseille, CEDEX 20/FR, ⁴Mulhouse, FR, ⁵Toulouse, FR, ⁶Mantes La Jolie, FR, ⁷Amiens, FR, ⁸Lyon, CEDEX 8/FR, ⁹Grenoble, FR, ¹⁰Paris, FR, ¹¹Rueil-Malmaison, FR, ¹²Vandoeuvre Les Nancy, FR, ¹³Uxbridge, GB, ¹⁴Toulon, CEDEX/FR

16:55 - 17:00 **1170 - Racial disparities in characteristics and prognosis in Asian versus white patients receiving atezolizumab: An ancillary analysis of POPLAR and OAK studies**

J. Qian, W. Nie, J. Lu, L. Zhang, Y. Zhang, B. Zhang, S. Wang, M. Hu, J. Xu, Y. Lou, Y. Dong, Y. Niu, B. Yan, R. Zhong, W. Zhang, T. Chu, H. Zhong, B. Han; Shanghai, CN



- 17:00 - 17:05 **1180 - Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials**
W. Nie, J. Qian, B. Han; Shanghai, CN
- 17:05 - 17:10 **1190 - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO**
C. Grohe¹, W. Gleiber², S. Haas³, H. Mueller-Huesmann⁴, M. Schulze⁵, J. Atz⁶, R. Kaiser⁶;
¹Berlin, DE, ²Frankfurt Am Main, DE, ³Neumünster, DE, ⁴Paderborn, DE, ⁵Zittau, DE, ⁶Ingelheim Am Rhein, DE
- 17:10 - 17:15 **1890 - EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases**
T. Jiang, C. Zhou; Shanghai, CN
- 17:15 - 17:40 **Discussion led by moderators**
- 16:45 - 17:45 Multiple lung tumour nodules Room B**
Moderation: M.S. Tsao¹, J. Zugazagoitia²; ¹Toronto, Ontario/CA, ²New Haven, US
- 16:45 - 16:45 **Session DOI**
- 16:45 - 17:05 **Treatment options from the medical oncologist's perspective**
J. Zugazagoitia, New Haven, US
- 17:05 - 17:25 **Surgical decision: To operate or not to operate?**
T. Mitsudomi, Osaka, JP
- 17:25 - 17:45 **The role of the pathologist: Multiple primaries vs metastatic disease**
M. Tsao, Toronto, Ontario/CA



16:45 - 17:45	Should we upfront NGS as a standard?	Room A
	Moderation: N. Normanno ¹ , L. Bubendorf ² ; ¹ Napoli, IT, ² Basel, CH	
16:45 - 16:45	Session DOI	
16:45 - 16:55	Introduction and first vote <u>L. Bubendorf</u> , Basel, CH	
16:55 - 17:15	Yes <u>F. Shepherd</u> , Toronto, Ontario/CA	
17:15 - 17:35	No <u>K. Kerr</u> , Aberdeen, GB	
17:35 - 17:45	Second vote and conclusions <u>N. Normanno</u> , Napoli, IT	
18:00 - 19:00	Boehringer Ingelheim - Industry Satellite Symposium	Room A
	Moderation: V. Gregorc, Milan, IT	
18:00 - 18:05	Meeting welcome and introductions <u>V. Gregorc</u> , Milan, IT	
18:05 - 18:20	Prolonging the chemotherapy-free period in EGFRM+ NSCLC <u>N. Girard</u> , Paris, FR	
18:20 - 18:30	Q&A: Treating EGFRM+ NSCLC <u>V. Gregorc</u> , Milan, IT	
18:30 - 18:45	Recent changes and sequencing strategies in non-mutated, non-squamous advanced NSCLC <u>M. Reck</u> , Grosshansdorf, DE	
18:45 - 18:55	Q&A: Treating non-mutated, non-squamous NSCLC <u>V. Gregorc</u> , Milan, IT	
18:55 - 19:00	Meeting close <u>V. Gregorc</u> , Milan, IT	



18:00 - 19:00 Medscape Oncology - Industry Satellite Symposium **Room C**
Moderation: S. Peters, Lausanne, CH

18:00 - 18:05 **Introduction**

S. Peters, Lausanne, CH

18:05 - 18:20 **Testing for ALK-positive disease: The state of the art**

R. Califano, Manchester, GB

18:20 - 18:35 **The expanding treatment armamentarium in ALK-positive NSCLC: The evidence**

M. Garassino, Milan, IT

18:35 - 18:45 **Case challenge 1: First-line options - Considerations for treatment choice**

M. Garassino, Milan, IT

18:45 - 18:55 **Case challenge 2: Second-line treatment selection - How do we choose?**

R. Califano, Manchester, GB

18:55 - 19:00 **Conclusions and key points**

S. Peters, Lausanne, CH



12.04.2019

08:30 - 10:00 Biomarker development in I-O **Room B**
Moderation: N. Normanno¹, S. Ramon y Cajal²; ¹Napoli, IT, ²Barcelona, ES

08:30 - 08:30 **Session DOI**

08:30 - 08:55 **Biomarkers for I-O**
L. Bubendorf, Basel, CH

08:55 - 09:20 **Role of biomarkers in resistance**
R.A. Soo, Singapore, SG

09:20 - 09:45 **How to implement immuno biomarkers in clinical practice**
S. Ramon y Cajal, Barcelona, ES

09:45 - 10:00 **Q&A**

08:30 - 10:00 Proffered Paper session III **Room A**
Moderation: T.S.K. Mok¹, N. Leigh²; ¹Shatin, HK, ²Toronto, CA

08:30 - 08:30 **Session DOI**

08:30 - 08:42 **840 - Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations**

B. Creelan¹, T. Yeh², S. Kim³, N. Nogami⁴, D. Kim³, L. Chow⁵, S. Kanda⁶, R. Taylor⁷, W. Tang⁸, M. Tang⁸, H. Angell⁷, M. Roudier⁷, M. Marotti⁷, D. Gibbons⁹; ¹Tampa, FL/US, ²Boston, MA/US, ³Seoul, KR, ⁴Matsuyama City, JP, ⁵Seattle, WA/US, ⁶Tokyo, JP, ⁷Cambridge, GB, ⁸Gaithersburg, MD/US, ⁹Houston, TX/US

08:42 - 08:54 **1040 - IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations**

M. Reck¹, R. Jotte², T.S.K. Mok³, D. Lim⁴, F. Cappuzzo⁵, F. Orlandi⁶, D. Stroyakovskiy⁷, N. Nogami⁸, D. Rodríguez-Abreu⁹, D. Moro-Sibilot¹⁰, C. Thomas¹¹, F. Barlesi¹², G. Finley¹³, M. Nishio¹⁴, A. Lee¹⁵, G. Shankar¹⁵, W. Yu¹⁵, M. Socinski¹⁶; ¹Grosshansdorf, DE, ²Denver, CO/US, ³Shatin, HK, ⁴Singapore, SG, ⁵Ravenna, IT, ⁶Santiago, CL, ⁷Moscow, RU, ⁸Matsuyama, JP, ⁹Las Palmas, ES, ¹⁰Grenoble, FR, ¹¹Scarborough, ME/US, ¹²Marseille, CEDEX 20/FR, ¹³Pittsburgh, PA/US, ¹⁴Tokyo, JP, ¹⁵South San Francisco, CA/US, ¹⁶Orlando, FL/US



- 08:54 - 09:06 **1050 - Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study**
M. Ahn¹, C. Chiu², Y. Cheng³, J. Han⁴, S. Goldberg⁵, A. Greystoke⁶, J. Crawford⁷, Y. Zhao⁸, X. Huang⁹, M. Johnson⁹, K. Vishwanathan¹⁰, A. Mendoza-Naranjo⁹, T.S.K. Mok¹¹;
¹Seoul, KR, ²Taipei, TW, ³Changchun, Jilin/CN, ⁴Goyang, KR/KR, ⁵New Haven, US,
⁶Newcastle Upon Tyne, Tyne and Wear/GB, ⁷Durham, NC/US, ⁸Zhengzhou, CN,
⁹Cambridge, GB, ¹⁰Waltham, US, ¹¹Shatin, HK
- 09:06 - 09:21 **Invited Discussant 840, 1040 and 1050**
P. Jänne, Boston, MA/US
- 09:21 - 09:33 **1060 - Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial**
R. Califano¹, M. Hochmair², C. Gridelli³, A. Delmonte⁴, M.R. Garcia Campelo⁵, A. Bearz⁶,
F. Griesinger⁷, A. Morabito⁸, E. Felip⁹, S. Ghosh¹⁰, M. Tiseo¹¹, J. Haney¹², D. Kerstein¹²,
S. Popat¹⁰, D. Camidge¹³; ¹Manchester, GB, ²Vienna, AT, ³Avellino, IT, ⁴Meldola, IT,
⁵Coruna, ES, ⁶Aviano, IT, ⁷Oldenburg, DE, ⁸Naples, IT, ⁹Barcelona, ES, ¹⁰London, GB,
¹¹Parma, IT, ¹²Cambridge, MA/US, ¹³Aurora, CO/US
- 09:33 - 09:45 **1070 - Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001**
A. Shaw¹, G. Riely², Y. Bang³, D. Kim³, D. Camidge⁴, G. Shapiro¹, T. Usari⁵, S. Wang⁶, K.
Wilner⁷, J. Clark¹, S. Ou⁸; ¹Boston, MA/US, ²New York, NY/US, ³Seoul, KR, ⁴Aurora,
CO/US, ⁵Milano, IT, ⁶La Jolla, CA/US, ⁷San Diego, US, ⁸Orange, CA/US
- 09:45 - 10:00 **Invited Discussant 1060 and 1070**
N. Leighl, Toronto, CA



08:30 - 10:00	Advanced nursing roles in LCC Moderation: D. Kelly ¹ , M. Culligan ² ; ¹ London, GB, ² Baltimore, MD/US	Room K
08:30 - 08:30	Session DOI	
08:30 - 08:35	Introduction <u>D. Kelly</u> , London, GB	
08:35 - 08:55	Advanced nursing practices in thoracic surgery: Improving patient outcomes <u>M. Culligan</u> , Baltimore, MD/US	
08:55 - 09:15	Developing advanced practice lung cancer nurses <u>M. Eicher</u> , Lausanne, CH	
09:15 - 09:35	Evaluation and challenges of advanced practice lung cancer nurses in current context <u>A. Tod</u> , Sheffield, GB	
09:35 - 09:55	RECaN: What this project has taught us about advanced roles? <u>D. Kelly</u> , London, GB	
09:55 - 10:00	Conclusions <u>M. Culligan</u> , Baltimore, MD/US	
10:00 - 10:30	Coffee break	Hall 1



10:30 - 12:00 **The accessibility and sustainability of lung cancer care** **Room C**
Moderation: A. Baird, Dublin, IE

10:30 - 10:30 **Session DOI**

10:30 - 10:35 **Introduction**

A. Baird, Dublin, IE

10:35 - 10:55 **Accessibility in low and middle-income countries**

E. Szmytke, Bern, CH

10:55 - 11:15 **Accessibility and sustainability of new expensive treatment**

M. Tran Minh, Helsinki, FI

11:15 - 11:35 **What can LuCE achieve in terms of lobbying?**

S. Vallone, Orbassano, IT

11:35 - 11:55 **Importance of access to innovative treatments and their impact on patient reported outcomes**

M. Hennink, Utrecht, NL

11:55 - 12:00 **Conclusions**

A. Baird, Dublin, IE



10:30 - 12:00 Genetic heterogeneity and clonal evolution **Room B**
Moderation: D.S.W. Tan¹, M. Peifer²; ¹Singapore, SG, ²Cologne, DE

10:30 - 10:30 **Session DOI**

10:30 - 10:50 **Clonal evolution in lung cancer**
N. McGranahan, London, GB

10:50 - 11:10 **Immune microenvironment and cancer evolution**
M. Holzel, Bonn, DE

11:10 - 11:30 **Elucidating EGFR evolution**
D.S.W. Tan, Singapore, SG

11:30 - 11:50 **Challenges in tracking clonal evolution**
M. Peifer, Cologne, DE

11:50 - 12:00 **Q&A**

10:30 - 12:00 Implementation of personalised lung cancer care in clinical routine **Room A**
Moderation: B. Besse¹, J. Wolf²; ¹Villejuif, CEDEX/FR, ²Cologne, DE

10:30 - 10:30 **Session DOI**

10:30 - 10:50 **Experiences from the German Network Genomic Medicine**
J. Wolf, Cologne, DE

10:50 - 11:10 **Reflections from the French experience**
B. Besse, Villejuif, CEDEX/FR

11:10 - 11:30 **How can ESMO help to implement personalised treatment in clinical practice**
R.A. Stahel, Zurich, CH

11:30 - 11:50 **The role of IASLC in helping to implement personalised medicine**
G. Scagliotti, Orbassano, TO/IT

11:50 - 12:00 **Q&A**



10:30 - 12:00	Family caregivers in LCC Moderation: A. Charalambous ¹ , C.L. Degi ² ; ¹ Limassol, CY, ² Cluj-Napoca, RO	Room K
10:30 - 10:30	DOI session	
10:30 - 10:35	Introduction	
10:35 - 11:00	The experience and impact of cancer caregiving through the cancer continuum <u>A. Charalambous</u> , Limassol, CY	
11:00 - 11:25	What caregivers do for patients affected by cancer? <u>H. Ullgren</u> , Stockholm, SE	
11:25 - 11:45	Family caregivers burnout <u>C. Degi</u> , Cluj-Napoca, RO	
11:45 - 12:00	Conclusions and Q&A <u>C. Degi</u> , Cluj-Napoca, RO	
12:10 - 12:40	A decade of targeting EGFR Moderation: J. Wolf, Cologne, DE	Room B
12:10 - 12:10	Session DOI	
12:10 - 12:40	A decade of targeting EGFR <u>T.S.K. Mok</u> , Shatin, HK	
12:30 - 13:00	Lunch & Poster Display session Moderation: B. Besse ¹ , A.C. Dingemans ² , D. De Ruysscher ² , D. Planchard ³ , N. Peled ⁴ , R. Buettner ⁵ , T. Behrens ⁶ ; ¹ Villejuif, CEDEX/FR, ² Maastricht, NL, ³ Villejuif, FR, ⁴ Beer Sheva, IL, ⁵ Cologne, DE, ⁶ Bochum, DE	Hall 1
12:30 - 12:30	3P - Notable variation of molecular testing in metastatic lung cancer in the Netherlands <u>C. Epskamp-Kuijpers</u> ¹ , M. Van den Heuvel ² , L. Overbeek ³ , A. Van Lindert ¹ , R. Damhuis ¹ , S. Willems ¹ ; ¹ Utrecht, NL, ² Nijmegen, NL, ³ Houten, NL	
12:30 - 12:30	4P - Correlation between folate receptor alpha (FRα) expression and clinicopathological features in lung adenocarcinoma	



N. Tamura¹, Y. Fujiwara¹, T. Hashimoto¹, H. Shiraishi¹, S. Kitano², T. Shimizu¹, N. Yamamoto¹, N. Motoi¹; ¹Tokyo, JP, ²Tokyo, NY/JP

- 12:30 - 12:30 **5P - The circular RNA circXPO1 promotes tumor growth in lung adenocarcinoma**
O. Huang, M. Qiu; Beijing, CN
- 12:30 - 12:30 **6P - Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with lung cancer**
C. Son, Busan, KR
- 12:30 - 12:30 **7P - Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models**
U. Weinberg¹, N. Kaynan², T. Voloshin Sela², S. Davidi², Y. Porat², A. Shteingauz², M. Munster², R. Schneiderman², C. Tempel Brami², E. Zeevi², K. Gotlib², S. Cahal², M. Giladi², E. Kirson², A. Kinzel³, Y. Palti²; ¹Luzern, CH, ²Haifa, IL, ³München, DE
- 12:30 - 12:30 **8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)**
M. Drosslerová, M. Šterclová, M. Vašáková, A. Tašková, V. Hytych, P. Horažďovský, E. Richterová, M. Smětáková, L. Havel; Prague, CZ
- 12:30 - 12:30 **9P - Clinical validation of an NGS-based assay for detecting multiple genomic alterations in Chinese patients with non-small cell lung cancer**
H. Ge¹, X. Chen², L. Ruan¹, Q. Gao¹, X. Yang¹, W. Shi¹, X. Li¹, G. Zhu¹; ¹Xiamen, CN, ²Fuzhou, CN
- 12:30 - 12:30 **10P - The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations**
W. Wang¹, C. Xu², Q. Zhang², W. Zhuang², Y. Zhu¹, Z. Huang², G. Chen², M. Fang¹, T. Lv³, Y. Song³; ¹Zhenjiang, CN, ²Fuzhou, CN, ³Nanjing, CN
- 12:30 - 12:30 **11P - Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells**
L. Liang, K. Hui, C. Hu, Y. Wen, X. Jiang; Lianyungang, CN
- 12:30 - 12:30 **12P - Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer**
Q. Zhang¹, C. Xu¹, W. Wang², W. Zhuang¹, Z. Huang¹, G. Chen¹, M. Fang², T. Lv³, Y. Song³; ¹Fuzhou, CN, ²Zhenjiang, CN, ³Nanjing, CN
- 12:30 - 12:30 **13P - The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact**
R. Shemesh¹, Y. Gorzalczany¹, R. Sagi-Eisenberg¹, S. Geva¹, L.R. Roisman², N. Peled²; ¹Tel Aviv, IL, ²Beer Sheva, IL



- 12:30 - 12:30 **14P - The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis**
Y. Zhu¹, C. Xu², W. Wang¹, Q. Zhang², W. Zhuang², G. Chen², M. Fang¹, T. Lv³, Y. Song³;
¹Zhenjiang, CN, ²Fuzhou, CN, ³Nanjing, CN
- 12:30 - 12:30 **15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor**
J.F. Cordoba Ortega¹, A. Salud², S. Morales², J. Veas², A. Rodriguez²; ¹Lleida, ES,
²Lerida, ES
- 12:30 - 12:30 **17P - REDOXI-miRNA of Keap1/Nrf2 axis in lung tumors**
F. Fabrizio, A. Sparaneo, S. Castellana, T. Mazza, D. Trombetta, P. Graziano, A. Rossi, V. Fazio, L.A. Muscarella; San Giovanni Rotondo, IT
- 12:30 - 12:30 **18P - Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features**
E. Kokkotou, V. Rapti, D. Grapsa, P. Bakakos, S. Papadopoulos, M. Bobos, K. Iliadis, K. Syrigos; Athens, GR
- 12:30 - 12:30 **19P - FOXP3³, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer**
H. JIA¹, H. Qi², J. Peng², M. Li², G. Chen¹; ¹Shatin, HK, ²Hong Kong, HK
- 12:30 - 12:30 **20P - Atypical hyperplasia of bronchial epithelial cells induced by chronic exposure to PM 2.5 in mice**
T.F. Hou, Q.H. Chen; Beijing, CN
- 12:30 - 12:30 **22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors**
D. Dumoulin¹, P. de Goeje², M. Poncin², K. Bezemer², H. Groen³, E. Smit⁴, A. Dingemans⁵, A. Kunert², R. Hendriks², J. Aerts⁶; ¹Barendrecht, NL, ²Rotterdam, NL, ³Groningen, NL, ⁴Amsterdam, NL, ⁵Maastricht, NL, ⁶Rotterdam, Noord Brabant/NL
- 12:30 - 12:30 **23P - Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)**
R. Ferrara¹, M. Naigeon², E. Auclin², B. Duchemann³, L. Cassard¹, J.J. Medhi², L. Boselli², J. Grivel², A. Desnoyer², L. Mezquita¹, L. Hendriks⁴, D. Planchard¹, C. Caramella¹, J. Remon-Masip⁵, S. Sangaletti⁶, M. Garassino⁷, B. Besse⁸, N. Chaput⁸;
¹Villejuif, FR, ²Paris, FR, ³Bobigny, CEDEX/FR, ⁴Maastricht, NL, ⁵Barcelona, ES, ⁶Milano, IT, ⁷Milan, IT, ⁸Villejuif, CEDEX/FR
- 12:30 - 12:30 **24P - A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation**



P. Manca¹, I. Mallona², D. Santini³, G. Tonini³, C. Rolfo⁴, M. Robinson², F. Pantano³;
¹Rome, IT, ²Zürich, CH, ³Roma, IT, ⁴Baltimore, US

- 12:30 - 12:30 **25P - Lung tumorspheres as a drug screening platform against cancer stem cells**
A. Herreros Pomares¹, H. Amado¹, S. Calabuig Fariñas¹, E. Escorihuela¹, J. Murga², S. Torres¹, E. Durendez-Saez¹, F. Zhang¹, A. Blasco¹, A. Navarro¹, C. Sampedro¹, E. Jantus-Lewintre¹, C. Camps¹; ¹Valencia, ES, ²Castellón, ES
- 12:30 - 12:30 **26P - Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy**
L. Bonanno, E. Zulato, I. Attili, A. Pavan, P. Del Bianco, G. Nardo, A. Boscolo Bragadin, L. Pasqualini, F. Calabrese, M. Fassan, G. Pasello, V. Guarneri, A. Amadori, P. Conte, S. Indraccolo; Padova, IT
- 12:30 - 12:30 **27P - Comparison of three different gene panels for determination of tumor mutational burden by next generation sequencing**
R. Pappesch, C. Heydt, J. Rehker, S. Merkelbach-Bruse; Köln, DE
- 12:30 - 12:30 **28P - Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients**
S. Calabuig Fariñas, A. Blasco, E. Durendez-Saez, A. Fernández, M. Mosqueda, E. Escorihuela, A. Herreros Pomares, F. Aparisi, J. Garde, M. Shahin, E. Jantus-Lewintre, C. Camps; Valencia, ES
- 12:30 - 12:30 **29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)**
O.J. Juan Vidal, J. Simarro, D. Lorente Estelles, G. Pérez-Simó, N. Mancheno, R. Murria, J. Gomez Codina, B. Laiz, S. Palanca; Valencia, ES
- 12:30 - 12:30 **30P - Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer**
I. Kotsantis, P. Economopoulou, A. Psyrri, E. Maratou, D. Pectasides, H. Gogas, N. Kentepozidis, G. Mountzios, G. Dimitriadis, S. Giannouli; Athens, GR
- 12:30 - 12:30 **31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer**
J. Domagala-Kulawik, T. Skirecki, D. Dziedzic, M. Polubiec-Kownacka, T. Kryczka, I. Kwiecien; Warsaw, PL
- 12:30 - 12:30 **32P - Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers**
E. Durendez-Saez¹, S. Calabuig Fariñas¹, C. Suarez², M. Mosqueda¹, S. Gallach¹, E. Escorihuela¹, A. Moreno¹, N. Dong¹, A. Herreros Pomares¹, E. de la Cueva¹, A. Martinez-Romero¹, E. Serna¹, J.M. Paramio², E. Jantus-Lewintre¹, C. Camps¹; ¹Valencia, ES, ²Madrid, ES



- 12:30 - 12:30 **33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy**
K. Gennen¹, L. Käsmann¹, C. Eze¹, M. Dantes¹, O. Roengvoraphoj¹, J. Taugner², J. Neumann², A. Tufman¹, M. Orth², S. Reu³, C. Belka¹, F. Manapov¹; ¹Munich, DE, ²München, DE, ³Würzburg, DE
- 12:30 - 12:30 **34P - Impacts of HDAC2 inhibition on lung cancer treatment**
Y. Yeh¹, C. Wu², J. Lai², C. Huang², Y. Wei², M. Huang²; ¹Kaohsiung City, TW, ²Kaohsiung, TW
- 12:30 - 12:30 **35P - Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population**
Y. Shen, F. Hu, B. Zhang, B. Han; Shanghai, CN
- 12:30 - 12:30 **36P - Can a BALF profile distinguish hot vs cold lung tumors?**
J. Domagala-Kulawik, D. Dziejczak, M. Polubiec-Kownacka, T. Kryczka, I. Kwiecien; Warsaw, PL
- 12:30 - 12:30 **37P - Genetic variation of lymphotoxin beta receptor (LT β ;R) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals**
F. Dimitrakopoulos¹, A. Antonacopoulou², A. Kottorou¹, V. Tzelepi², N. Panagopoulos², M. Kalofonou³, D. Dougenis², A. Koutras², T. Makatsoris¹, H. Kalofonos²; ¹Patras, Rion/GR, ²Patras, GR, ³London, GB
- 12:30 - 12:30 **38P - Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells**
Y. Liu, R. Kiefl, R. Huber, A. Tufman, D. Kauffmann-Guerrero; Munich, DE
- 12:30 - 12:30 **39P - High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma**
L. Liang, C. Hu, Y. Wen, W. Zhuang, L. Wang, Y. Xia, K. Hui, X. Jiang; Lianyungang, CN
- 12:30 - 12:30 **40P - The metabolic phenotypes of non-small cell lung cancer cells in association with clinical treatment strategies**
T. Kuo¹, T. Hsiao², P. Yang¹; ¹Taipei, TW, ²Taichung, TW
- 12:30 - 12:30 **41P - Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis**
C. Li, Q. He, H. Liang, J. He, W. Liang; Guangzhou, CN
- 12:30 - 12:30 **44P - Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative**



M. Snee¹, S. Cheeseman¹, M. Thompson², M. Riaz¹, L. Lacoïn³, W. Sopwith¹, C. Chaib⁴, M. Daumont⁵, J. Penrod⁶, J. O'Donnell⁶, G. Hall¹; ¹Leeds, GB, ²London, GB, ³Ladeuze, BE, ⁴Madrid, ES, ⁵Braine-L'alleud, BE, ⁶Princeton, NJ/US

- 12:30 - 12:30 **45P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative**
M. Soares¹, L. Antunes¹, P. Redondo¹, M. Borges¹, R. Hermans², D. Patel², F. Grimson², R. Munro², C. Chaib³, L. Lacoïn⁴, M. Daumont⁵, J. Penrod⁶, J. O'Donnell⁶, M. Bento¹, F.R. Goncalves¹; ¹Porto, PT, ²London, GB, ³Madrid, ES, ⁴Ladeuze, BE, ⁵Braine-L'alleud, BE, ⁶Princeton, NJ/US
- 12:30 - 12:30 **46P - Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative**
J. Sørensen¹, S. Ekman², O.T. Brustugun³, P. Horvat⁴, D. Patel⁴, M. Rosenlund², A. Mette Kejs¹, A. Juarez-Garcia⁵, M. Daumont⁶, L. Lacoïn⁷, J. Penrod⁸, J. O'Donnell⁸, M. Planck⁹; ¹Copenhagen, DK, ²Stockholm, SE, ³Oslo, NO, ⁴London, GB, ⁵Uxbridge, GB, ⁶Braine-L'alleud, BE, ⁷Ladeuze, BE, ⁸Princeton, NJ/US, ⁹Lund, SE
- 12:30 - 12:30 **47P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative**
S. Ekman¹, J. Sørensen², O.T. Brustugun³, P. Horvat⁴, D. Patel⁴, M. Rosenlund¹, A. Mette Kejs², A. Juarez-Garcia⁵, M. Daumont⁶, L. Lacoïn⁷, J. Penrod⁸, J. O'Donnell⁸, M. Planck⁹; ¹Stockholm, SE, ²Copenhagen, DK, ³Oslo, NO, ⁴London, GB, ⁵Uxbridge, GB, ⁶Braine-L'alleud, BE, ⁷Ladeuze, BE, ⁸Princeton, NJ/US, ⁹Lund, SE
- 12:30 - 12:30 **48P - Education and lung cancer: A Mendelian randomisation study**
H. Zhou, Y. Zhang, J. Liu, Y. Yang, W. Fang, S. Hong, G. Chen, S. Zhao, Z. Zhang, J. Shen, W. Xian, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN
- 12:30 - 12:30 **49P - A Mendelian randomization study of the effects of Crohn’s disease on lung cancer**
J. Liu, H. Zhou, Y. Zhang, W. Fang, Y. Yang, S. Hong, G. Chen, S. Zhao, J. Shen, W. Xian, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN
- 12:30 - 12:30 **50P - Reduced-, and no-dose thin-section radiologic examinations: Comparison of capability for nodule detection in patients having pulmonary nodules**
W. Tang, Q. Peng, Y. Huang, N. Wu, H. Ouyang; Beijing, CN
- 12:30 - 12:30 **51P - Invasive diagnostic investigation-related complications and its impact on treatment initiation in lung cancer patients in a rapid access lung lesion clinic in regional Australia**
K. Mccann¹, W. Faisal²; ¹Ballarat, VIC/AU, ²Ballarat, AU
- 12:30 - 12:30 **52P - Concordance, decision impact, and satisfaction for a computerized clinical decision support system in treatment of lung cancer patients**



K.A. Lee¹, W. Felix², G. Jackson³; ¹Jupiter, US, ²Boston, MA/US, ³Nashville, TN/US

- 12:30 - 12:30 **53P - Pulmonary tuberculosis: A hurdle to overcome for early lung cancer diagnosis in TB burden countries**
M.S. Akter, S. Ahmed; Dhaka, BD
- 12:30 - 12:30 **56P - CT image standardization is superior to larger but heterogeneous data for robust radiomic models**
D. Vuong¹, M. Bogowicz¹, J. Unkelbach¹, R. Foerster¹, S. Denzler¹, A. Xyrafas², M. Pless³, S. Thierstein², S. Peters⁴, M. Guckenberger¹, S. Tanadini-Lang¹; ¹Zürich, CH, ²Bern, CH, ³Winterthur, CH, ⁴Lausanne, CH
- 12:30 - 12:30 **57P - Non-small cell lung carcinoma (NSCLC) patients with baseline brain imaging: A prospective observational study**
G. NARESH, P.S. Malik, S. Khurana, S. Pathy, M. Yadav, D. Jain, H. Kancharla; New Delhi, IN
- 12:30 - 12:30 **58P - Evaluation of a care path for patients with lung tumors and co-existing interstitial lung disease**
M. Ronden-Kianoush, E. Nossent, C. Dickhoff, S. Nijman, I. Bahce, S. Senan, F. Spoelstra; Amsterdam, NL
- 12:30 - 12:30 **59P - Comparison of internal target volume delineation using CT datasets of four-dimensional computed tomography in lung cancer radiotherapy**
S. Bushra, A. Tibdewal, N. Mummudi, R. Kinhikar, Y. Ghadi, J.P. Agarwal; Mumbai, IN
- 12:30 - 12:30 **60P - Nomogram for patients with stage I small cell lung cancer: A competing risk analysis**
J. Liu, H. Zhou, Y. Zhang, W. Fang, Y. Yang, S. Hong, G. Chen, S. Zhao, X. Chen, Z. Zhang, W. Xian, J. Shen, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN
- 12:30 - 12:30 **61P - Value of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model**
J. Yu, W. Ouyang, J. Hu, J. Zhang, C. Xie; Wuhan, CN
- 12:30 - 12:30 **62P - External validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy**
L. Käsmann¹, R. Abdo², J. Taugner², C. Eze¹, M. Dantes¹, O. Roengvoraphoj¹, C. Belka¹, F. Manapov¹; ¹Munich, DE, ²München, DE
- 12:30 - 12:30 **63P - Real-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients**
M. Hochmair, C. Weinlinger, H. Fabikan, R. Koger, D. Krenbeck, F. Huemer, O. Illini, M. Kulaksiz, A. Valipour, O. Burghuber; Vienna, AT



- 12:30 - 12:30 **64P - Timing of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC)**
L. McSorley¹, C. Goggin², N. Elhadi², P. O'Dea², J. Sui³, D. Kelly³, C. Brady⁴, D. O'Mahony⁴; ¹Galway, IE, ²Cork, IE, ³Dublin, IE, ⁴Cork, Cork/IE
- 12:30 - 12:30 **65P - Experience of prophylactic cranial irradiation in extensive stage small cell lung cancer at a regional cancer center in India**
R. Jat, R. Rai, S. Jakhar, S. Beniwal, N. Sharma, H. Kumar; Bikaner, IN
- 12:30 - 12:30 **66P - Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice**
M. Sebastian¹, F. Barlesi², R. Califano³, A. Mansfield⁴, F. Blackhall³, E. Flahavan⁵, J. Davies⁵, P. Arnold⁶, S. Morris⁶, M. Reck⁷; ¹Frankfurt Am Main, DE, ²Marseille, CEDEX 20/FR, ³Manchester, GB, ⁴Rochester, MN/US, ⁵Welwyn Garden City, GB, ⁶Basel, CH, ⁷Grosshansdorf, DE
- 12:30 - 12:30 **67TiP - ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer**
S. Senan¹, N. Shire², G. Mak³, W. Yao³, H. Jiang⁴; ¹Amsterdam, NL, ²Gaithersburg, US, ³Gaithersburg, MD/US, ⁴Shanghai, CN
- 12:30 - 12:30 **73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries**
R. Damhuis¹, S. Senan², A. Khakwani³, S. Harden⁴, A. Helland⁵, T. Strand⁵; ¹Utrecht, NL, ²Amsterdam, NL, ³Nottingham, GB, ⁴Cambridge, GB, ⁵Oslo, NO
- 12:30 - 12:30 **74P - Is there any prognostic significance of the level of change in SUVmax after SBRT in patients with early stage NSCLC?**
G. Yaprak¹, A. Ozen², F. Tugrul², S. Ozugur¹, N. Isik¹; ¹Istanbul, TR, ²Eskisehir, TR
- 12:30 - 12:30 **75P - Thoracic ultrasound can be a trustable tool in untouchable lung nodule surgery**
H. Zhang, Berlin, CN
- 12:30 - 12:30 **76P - Endobronchial surgery and photodynamic therapy for early central lung cancer treatment**
S. Pirogov, L. Telegina, V. Sokolov, T. Karmakova, E. Filonenko, O. Pikin, A. Kaprin; Moscow, RU
- 12:30 - 12:30 **77P - The prognostic impact of the international association for the study of lung cancer (IASLC) definitions on completeness of surgical resection for non-small cell lung cancer (NSCLC)**



M. Gagliasso¹, C. Cartia², A. Maraschi², R. Rapanà², S. Sobrero², A. Sandri², G. Migliaretti², F. Ardisson²; ¹Cuneo, IT, ²Orbassano, IT

- 12:30 - 12:30 **78P - Lung resection for cancer in patients with heart disease: Management and postoperative outcome**
F. Caushi, I. Skenduli, A. Hatibi, A. Mezini, S. Telo, S. Bala, E. Shima, A. Cani; Tirana, AL
- 12:30 - 12:30 **79P - Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer**
X. Chen, Y. Deng, Y. Shi; Fuzhou, CN
- 12:30 - 12:30 **80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)**
J.F. Cordoba Ortega¹, A. Salud², S. Morales², J. Veas², A. Rodriguez²; ¹Lleida, ES, ²Lerida, ES
- 12:30 - 12:30 **81P - Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer**
P. Rocha, M. Rodrigo, L. Moliner, M. Hardy-Werbin, D. Casadevall Aguilar, X. Durán, O. Arpí, S. Clavé, M. Salido, X. Riera, S. Menendez, Á. Taus, L. Pijuan, L. Comerma, E. Arriola Aperribay; Barcelona, ES
- 12:30 - 12:30 **82TiP - IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) & chemotherapy**
S. Peters¹, A. Kim², B. Solomon³, D. Gandara⁴, R. Dziadziuszko⁵, A. Brunelli⁶, M. Garassino⁷, M. Reck⁸, L. Wang⁹, I. To⁹, S. Sun⁹, B. Gitlitz⁹, A. Sandler¹⁰, N. Rizvi¹¹; ¹Lausanne, CH, ²Los Angeles, CA/US, ³Melbourne, VIC/AU, ⁴Sacramento, CA/US, ⁵Gdańsk, PL, ⁶Leeds, GB, ⁷Milan, IT, ⁸Grosshansdorf, DE, ⁹South San Francisco, CA/US, ¹⁰South San Francisco, OR/US, ¹¹New York, NY/US
- 12:30 - 12:30 **87P - Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients**
A. Prelaj¹, S.E. Rebuzzi², P. Pizzutilo³, M. Bilancia³, M. Montrone³, F. Pesola³, V. Longo³, G. Del Bene³, V. Lapadula³, F. Cassano³, P. Petrillo³, D. Bafunno³, N. Varesano³, V. Lamorgese³, A. Mastranrdea³, D. Ricci³, A. Catino³, D. Galetta³; ¹Milan, IT, ²Genova, IT, ³Bari, IT
- 12:30 - 12:30 **89P - Treatment patterns and long-term survival for unresected stage III non-small cell lung cancer patients: A nationwide register study in Denmark**
A. Green¹, K. Olsen², M. Bliddal², H. Christensen¹, E. Jakobsen²; ¹Copenhagen, DK, ²Odense C, DK
- 12:30 - 12:30 **90P - Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database**



N. Girard¹, M. Pérol², G. Simon¹, C. Audigier Valette³, R. Gervais⁴, D. Debieuvre⁵, R. Schott⁶, X. Quantin⁷, B. Coudert⁸, H. Lena⁹, M. Carton¹, M. Robain¹, T. Filleron¹⁰, C. Chouaid¹¹; ¹Paris, FR, ²Lyon, CEDEX/FR, ³Toulon, CEDEX/FR, ⁴Caen, CEDEX 5/FR, ⁵Mulhouse, FR, ⁶Strasbourg, CEDEX/FR, ⁷Montpellier, CEDEX 5/FR, ⁸Dijon, Cedex/FR, ⁹Rennes, CEDEX/FR, ¹⁰Toulouse, CEDEX 3/FR, ¹¹Créteil, CEDEX 12/FR

- 12:30 - 12:30 **91P - Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns**
F. Hu¹, B. Zhang¹, C. Li¹, J. Xu¹, H. Wang¹, P. Gu¹, X. Zheng¹, W. Nie¹, Y. Shen¹, H. Zhang¹, P. Hu², X. Zhang¹; ¹Shanghai, CN, ²Zhenjiang, CN
- 12:30 - 12:30 **92P - A prospective study on the association of dose-volume histogram parameters with oesophagitis, radiation pneumonitis, radiation induced pulmonary fibrosis after receiving chemoradiation for NSCLC**
S. Bhowal, K. Chatterjee, J. Dey; Kolkata, IN
- 12:30 - 12:30 **93P - Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis**
J. Taugner¹, L. Käsmann², C. Eze², M. Dantes², O. Roengvoraphoj², K. Gennen², M. Karin², A. Tufman², C. Belka², F. Manapov²; ¹München, DE, ²Munich, DE
- 12:30 - 12:30 **94P - Challenges in the management of stage III non-small cell lung cancer (NSCLC) within multidisciplinary team (MDT): A lung cancer center experience**
K. Harbeque, N. Mejri, H. El Benna, S. Labidi, N. Daoud, H. Boussen; Ariana, TN
- 12:30 - 12:30 **95P - The role of patient performance status and its changes before and after completion of multimodal treatment for inoperable stage III NSCLC**
L. Käsmann¹, J. Taugner², C. Eze¹, O. Roengvoraphoj¹, M. Dantes¹, K. Gennen¹, M. Karin¹, A. Tufman¹, C. Belka¹, F. Manapov¹; ¹Munich, DE, ²München, DE
- 12:30 - 12:30 **96P - Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC**
M. Hoffmann¹, J. Taugner¹, O. Roengvoraphoj², C. Eze², L. Käsmann², C. Belka², F. Manapov²; ¹München, DE, ²Munich, DE
- 12:30 - 12:30 **97P - Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy**
C. Eze¹, J. Taugner², L. Käsmann¹, O. Roengvoraphoj¹, N. Schmidt-Hegemann², M. Dantes¹, C. Belka¹, F. Manapov¹; ¹Munich, DE, ²München, DE
- 12:30 - 12:30 **98P - Implications for UK practice of the use of durvalumab in stage III NSCLC**



M.S. Iqbal¹, P. Atherton¹, C. Macgregor², A. Wieczorek³, J. Singer⁴, J. Walther⁵, F. Little⁶, S. Harden⁷, C. Peedell⁸, A. Cyriac⁹, S. Chowdhury⁴, M. Bayne¹⁰, K. Yip¹¹, A. Britten¹², C. Powell¹³, J. Brock¹², S. Datta¹⁴, T. Sevitt¹⁵, A. Mehta¹⁶, A. Greystoke¹⁷; ¹Newcastle Upon Tyne, GB, ²Inverness, GB, ³Cottingham, GB, ⁴Harlow, GB, ⁵Taunton, GB, ⁶Edinburgh, GB, ⁷Cambridge, GB, ⁸Middlesbrough, GB, ⁹Southend, GB, ¹⁰Poole, GB, ¹¹Ipswich, GB, ¹²Brighton, GB, ¹³Swansea, GB, ¹⁴Peterborough, GB, ¹⁵Maidstone, GB, ¹⁶Guildford, GB, ¹⁷Newcastle Upon Tyne, Tyne and Wear/GB

12:30 - 12:30

99P - Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence

F. Roitberg¹, M.F. Neffá¹, R. Bonadio¹, G. Harada¹, E. Mendoza², M. Mak¹, T. Takahashi¹, R. Martins¹, C. Mesquita¹, F. Santini¹, P. de Araújo¹, L. Lauricella¹, G. Prado¹, T. Takagaki¹, E. de Mello¹, F. Gabrielli¹, H. de Andrade Carvalho¹, R. Terra¹, G. de Castro Jr³; ¹Sao Paulo, BR, ²Quito, EC, ³São Paulo, BR

12:30 - 12:30

100P - A new PET-CT score for locally-advanced inoperable NSCLC stage III patients treated with chemoradiotherapy

O. Roengvoraphoj¹, C. Eze¹, J. Taugner², A. Gjika², A. Tufman¹, L. Käsmann¹, I. Hadi², E. Mille², C. Belka¹, F. Manapov¹; ¹Munich, DE, ²München, DE

12:30 - 12:30

101TiP - PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy

N. Girard¹, F. Mornex², D. Christoph³, R. Fietkau⁴, A. Filippi⁵, J. Field⁶, P. Garrido Lopez⁷, F. McDonald⁸, S. Peters⁹, A. Klein¹⁰, M. Licour¹¹, M. Garassino¹²; ¹Paris, FR, ²Pierre Bénite, FR, ³Essen, DE, ⁴Erlangen, DE, ⁵Pavia, IT, ⁶Liverpool, GB, ⁷Madrid, ES, ⁸London, GB, ⁹Lausanne, CH, ¹⁰Cambridge, GB, ¹¹Gaithersburg, US, ¹²Milan, IT

12:30 - 12:30

121P - Risk of not receiving second-line therapy is high in EGFR mt&&

J. Roeper¹, A. Lueers², M. Falk³, S. Schatz⁴, M. Tiemann⁴, C. Wesseler⁴, G.H. Wiest⁴, S. Sackmann⁵, D. Ukena⁵, L. Heukamp⁶, F. Griesinger²; ¹Berlin, DE, ²Oldenburg, DE, ³Hamburg, Hamburg/DE, ⁴Hamburg, DE, ⁵Bremen, DE, ⁶Köln, DE

12:30 - 12:30

122P - Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts

J.C. Yang¹, S. Ramalingam², C. Lee³, T. Kurata⁴, D. Kim⁵, T. John⁶, N. Nogami⁷, Y. Ohe⁸, Y. Rukazenzov⁹, M. Murphy¹⁰, P. Jänne¹¹; ¹Taipei City, TW, ²Atlanta, US, ³Kogarah, NSW/AU, ⁴Osaka, JP, ⁵Seoul, KR, ⁶Heidelberg, AU, ⁷Matsuyama, JP, ⁸Tokyo, JP, ⁹Macclesfield, Cheshire/GB, ¹⁰Cambridge, GB, ¹¹Boston, MA/US

12:30 - 12:30

123P - Long term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-word study in China

S. Wang, B. Han; Shanghai, CN

12:30 - 12:30

124P - The effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation



J. Li, D. Nickens, K. Wilner, W. Tan; San Diego, US

- 12:30 - 12:30 **125P - Elderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON**
W. Brückl¹, E. Laack², C. Kortsik³, H. Schaefer⁴, M. Reck⁵, A. Maerten⁶, C. Hoffmann⁶;
¹Nürnberg, DE, ²Berlin, DE, ³Mainz, DE, ⁴Völklingen, DE, ⁵Grosshansdorf, DE,
⁶Ingelheim Am Rhein, DE
- 12:30 - 12:30 **126P - Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire**
D. Sharma¹, F. Slevin¹, K. Clarke¹, K. Franks², M. Snee¹, P. Jain¹; ¹Leeds, GB, ²Leeds, Yorkshire/GB
- 12:30 - 12:30 **127P - Obesity has an impact on the efficacy of EGFR-TKI in NSCLC patients harbouring EGFR mutation: A real-world study**
Z. Ding, Y. Chen, Y. Hong, Y. Fu, L. Tong, Q. Li, P. Lin; Chengdu, CN
- 12:30 - 12:30 **128P - Frequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer**
M. Sow, H. El Yacoubi¹, B. Moukafih, S. Balde, G. Akimana, S. Elkhoyaali, H. Abahssain, H. Mrabti, I. Elghissassi, H. Errihani; Rabat, MA
- 12:30 - 12:30 **129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer**
Z. Lian, W. Du, J. Zhu, Y. Zeng, L. zeyi, J. Huang; Suzhou, CN
- 12:30 - 12:30 **130P - Relationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion**
J. Zhang, Z. Zhou, Y. Su, T. Yu; Nanning, CN
- 12:30 - 12:30 **131P - Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma**
C. Li, J. Guo, L. Zhao, F. Hu, W. Nie, H. Wang, X. Zheng, Y. Shen, P. Gu, Y. Zhang, X. Zhang; Shanghai, CN
- 12:30 - 12:30 **132P - New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer**
J. Fassunke¹, C. Heydt², S. Michels², B. Van Veggel³, F. Müller², M. Keul⁴, M.A. Dammert², A. Schmitt², E. Smit³, S. Kast⁴, J. Wolf¹, R. Buettner¹, M. Sos², D. Rauh⁴, S. Merkelbach-Bruse²; ¹Cologne, DE, ²Köln, DE, ³Amsterdam, NL, ⁴Dortmund, DE
- 12:30 - 12:30 **133P - A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant**
J. Qu, L. Liu, J. Heng, C. Zhou, Y. Xiong, W. Jiang, N. Yang; Changsha, CN



- 12:30 - 12:30 **134P - Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors**
S. Wagener-Rydzek¹, C. Heydt², J. Sueptitz², S. Michels², M. Falk³, C. Alidousty², J. Fassunke¹, M. Tiemann⁴, L. Heukamp², J. Wolf¹, R. Buettner¹, S. Merkelbach-Bruse²; ¹Cologne, DE, ²Köln, DE, ³Hamburg, Hamburg/DE, ⁴Hamburg, DE
- 12:30 - 12:30 **135P - EGFR & PD L1: An (im)perfect union**
U. Batra¹, M. Sharma², P. Jain², S. Bothra², S. Pasricha³; ¹New Delhi, Rohini/IN, ²New Delhi, IN, ³Delhi, IN
- 12:30 - 12:30 **136P - Correlation of molecular status and anatomic sites of metastases at diagnosis of EGFR positive non-small cell lung cancer (NSCLC): A single institution experience**
K. Krpina, B. Budimir, S. Kukulj, A. Marušić, M. Jakopović, M. Samaržija; Zagreb, HR
- 12:30 - 12:30 **137P - Detection and clinicopathologic features of ctDNA in T790M-positive advanced lung adenocarcinomas patients after failure of treatment with first- and second-generation EGFR-TKIs**
W. he, Z. Zhou, T. Yu, H. Zhao, Y. Su, P. Zeng; Nanning, CN
- 12:30 - 12:30 **138P - PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype**
Y. Zhang, T. Liu, Y. Zeng, J. Zhu, W. Du, L. zeyi, J. Huang; Suzhou, CN
- 12:30 - 12:30 **139P - Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK&) non-small cell lung cancer (NSCLC) in the United States**
X. Pan¹, M. Lin², Y. Yin¹, P. Hou¹, P. Baumann¹, M. Jahanzeb³; ¹Cambridge, MA/US, ²Cambridge, US, ³Miami, FL/US
- 12:30 - 12:30 **140P - Brigatinib experience on the ALK project**
F. Gomes¹, N. Tokaca², K. Yip³, S. Ghosh², T. Newsom-Davis², A. Greystoke⁴, H. Mills², S. Ahmed⁵, A. Harle¹, G. Ayre⁶, R. Shah⁷, S. Popat², F. Blackhall¹, Y. Summers¹; ¹Manchester, GB, ²London, GB, ³Ipswich, GB, ⁴Newcastle Upon Tyne, Tyne and Wear/GB, ⁵Leicester, GB, ⁶Bristol, GB, ⁷Maidstone, Kent/GB
- 12:30 - 12:30 **141P - Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)**



L. Angelats¹, M.R. Garcia Campelo², R. Bernabe Caro³, E. Arriola Aperrribay⁴, V. Calvo de Juan⁵, A. Barba Joaquín⁴, N. Vinolas Segarra⁴, M. Gil Moreno⁶, L. Vilà Martinez⁷, O.J. Juan Vidal⁸, N. Vilariño Quintela⁴, M. Cobo⁹, E. Sais¹⁰, M. Domine Gomez¹¹, N. Fernandez Nuñez¹², J. Coves Sarto¹³, R. Marse Fabregat¹⁴, A.M. Esteve Gomez¹, D. Rodríguez-Abreu¹⁵, E. Carcereny Costa¹⁶; ¹Badalona, ES, ²Coruna, ES, ³Sevilla, ES, ⁴Barcelona, ES, ⁵Majadahonda, Madrid/ES, ⁶Barcelona, Barcelona/ES, ⁷Sabadell, Barcelona/ES, ⁸Valencia, ES, ⁹Malaga, ES, ¹⁰Girona, ES, ¹¹Madrid, ES, ¹²Lugo, ES, ¹³Palma De Mallorca, Islas Baleares/ES, ¹⁴Palma De Mallorca, ES, ¹⁵Las Palmas, ES, ¹⁶Badalona, Barcelona/ES

- 12:30 - 12:30 **142P - Clinical management of advanced lung adenocarcinoma with ALK rearrangement: Real-world treatment outcomes and long-term survival**
B. Zhang, S. Wang, J. Xu, Y. Zhang, X. Zhang, J. Qian, J. Lu, R. Qiao, W. Nie, L. Zhang, Y. Zhao, M. Hu, W. Zhang, B. Han; Shanghai, CN
- 12:30 - 12:30 **143P - Role of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study**
Y. Zhao, B. Zhang, Y. Zhang, S. Wang, J. Qian, B. Han; Shanghai, CN
- 12:30 - 12:30 **144P - Clinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs**
A. Passaro, A. Prelaj, G. Spitaleri, E. Del Signore, G. Rossi, E. Guerini-Rocco, M. Barberis, C. Catania, F. de Marinis; Milan, IT
- 12:30 - 12:30 **145P - Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients**
C.Y.X. Kho, D. Lim, D.S.W. Tan, W.L. Tan, T. Rajasekaran, A. Jain, C.K. Toh, M. Ang, E.H. Tan, Q.S. Ng; Singapore, SG
- 12:30 - 12:30 **146P - Clinical significance of ROS1 deletions detected by FISH and response to crizotinib**
F. Dall'Olio, G. Lamberti, E. Capizzi, E. Gruppioni, F. Sperandi, A. Altimari, F. Giunchi, M. Fiorentino, A. Ardizzoni; Bologna, IT
- 12:30 - 12:30 **147P - Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 mutations in non-small cell lung cancer (NSCLC)**
M. Scheffler¹, R. Frank², M. Ihle², D. Abdulla¹, S. Koleczko², L. Nogova², A. Holzem², T. Chanra¹, R. Riedel¹, S. Michels², R. Fischer², A. Kron¹, S. Merkelbach-Bruse², R. Buettner², J. Wolf¹; ¹Cologne, DE, ²Köln, DE
- 12:30 - 12:30 **148P - KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC**
M. Cinausero¹, N. Laprovitera², G. De Maglio¹, L. Gerratana¹, M. Riefolo², M. Macerelli¹, M. Fiorentino², E. Porcellini², V. Buoro¹, F. Gelsomino², A. Squadrilli³, G. Fasola¹, M. Tiseo³, M. Ferracin², A. Ardizzoni²; ¹Udine, IT, ²Bologna, IT, ³Parma, IT



- 12:30 - 12:30 **149P - Efficacy of tyrosine kinase inhibitors (TKIs) in advanced lung adenosquamous carcinoma**
M. Hu, B. Zhang, S. Wang, Y. Shen, J. Qian, Y. Zhao, B. Han; Shanghai, CN
- 12:30 - 12:30 **150P - Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy**
G. Galli¹, C. Proto², D. Signorelli¹, M. Imbimbo¹, R. Ferrara², A. Prelaj², A. De Toma², G. Randon², B. Trevisan², M. Ganzinelli², N. Zilembo², M. Garassino¹, G. Lo Russo²; ¹Milan, IT, ²Milano, IT
- 12:30 - 12:30 **151P - Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study**
H. Horinouchi¹, N. Nogami², H. Saka³, M. Nishio¹, T. Tokito⁴, T. Takahashi⁵, K. Kasahara⁶, Y. Hattori⁷, E. Ichihara⁸, N. Adachi¹, T. Sawada¹, T. Shimamoto¹, K. Noguchi¹, M.C. Pietanza⁹, T. Kurata¹⁰; ¹Tokyo, JP, ²Matsuyama, JP, ³Nagoya, JP, ⁴Kurume, JP, ⁵Shizuoka, Shizuoka/JP, ⁶Kanazawa, JP, ⁷Akashi, JP, ⁸Okayama, JP, ⁹Kenilworth, NJ/US, ¹⁰Osaka, JP
- 12:30 - 12:30 **152P - Correlation among different KRAS alterations, genetic co-mutations and PD-L1 expression in patients treated with immunotherapy in metastatic NSCLC**
L. Gianoncelli¹, G. Spitaleri¹, A. Passaro¹, C. Fumagalli¹, P. Trillo Aliaga¹, E. Del Signore², V. Stati¹, E. Ferraro³, E. Guerini-Rocco¹, C. Catania¹, M. Barberis¹, F. de Marinis¹; ¹Milan, IT, ²Roma, IT, ³Rozzano, (MI)/IT
- 12:30 - 12:30 **153P - Chemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis**
A. Addeo¹, G. Banna², G. Metro³, M. Di Maio⁴; ¹Geneva, CH, ²Catania, IT, ³Perugia, (PG)/IT, ⁴Torino, IT
- 12:30 - 12:30 **154P - Renal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy**
D. Dumoulin¹, S. Visser², R. Cornelissen³, J. Aerts⁴; ¹Barendrecht, NL, ²Breda, NL, ³Rotterdam, NL, ⁴Rotterdam, Noord Brabant/NL
- 12:30 - 12:30 **155P - Association of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC)**
C. Saavedra Serrano, A. Barquín García, E. Corral de la Fuente, J.J. Serrano Domingo, V. Albarrán Artahona, R. Martín Huertas, A. Gómez Rueda, M.E. Olmedo García; Madrid, ES
- 12:30 - 12:30 **156P - Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients**



A. Prelaj¹, S.E. Rebutzi², P. Pizzutilo³, M. Bilancia³, M. Montrone³, F. Pesola³, V. Longo³, G. Del Bene³, V. Lapadula³, F. Cassano³, P. Petrillo³, D. Bafunno³, N. Varesano³, V. Lamorgese³, A. Mastranrdea³, D. Ricci³, A. Catino³, D. Galetta³; ¹Milan, IT, ²Genova, IT, ³Bari, IT

12:30 - 12:30 **157P - Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies**

A. Schett¹, S. Rothschild¹, L. Mauti², S. Schmid², C. Appenzeller², A. Curioni-Fontecedro³, M. Frueh², M. Joerger²; ¹Basel, CH, ²St. Gallen, CH, ³Zurich, CH

12:30 - 12:30 **158P - Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse**

A. Pavan¹, L. Calvetti², A. Dal Maso¹, I. Attili¹, G. Pasello¹, G. Aprile³, V. Guarneri¹, P. Conte¹, L. Bonanno¹; ¹Padova, IT, ²Verona, IT, ³Vicenza, IT

12:30 - 12:30 **159P - Initial serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC**

D. Lang, A. Horner, E. Brehm, K. Akbari, B. Hergan, K. Langer, C. Asel, M. Scala, B. Kaiser, B. Lamprecht; Linz, AT

12:30 - 12:30 **160P - EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy**

A. Prelaj¹, G. Lo Russo², D. Signorelli¹, R. Ferrara², M. Imbimbo¹, G. Galli¹, A. De Toma², G. Randon², M. Brambilla¹, B. Trevisan², M. Ganzinelli², N. Zilembo², F. De Braud¹, M. Garassino¹, C. Proto²; ¹Milan, IT, ²Milano, IT

12:30 - 12:30 **161P - Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer**

P. Jermann¹, I. Alborelli¹, K. Leonards¹, S. Rothschild¹, L. Leuenberger¹, S. Savic Prince¹, K. Mertz², S. Poechtrager², A. Zippelius¹, L. Quagliata¹, L. Bubendorf¹; ¹Basel, CH, ²Liestal, CH

12:30 - 12:30 **162P - Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCCLC)**

V. Di Noia¹, E. D'Argento¹, E. Vita¹, M. Ferrara¹, P. Damiano¹, M. Ribelli¹, A. Cannella¹, A. Virtuoso¹, G. Tortora¹, E. Bria²; ¹Rome, IT, ²Roma, IT

12:30 - 12:30 **163P - Immuno-oncological treatment and tumor load in non-small cell lung cancer (NSCLC): Case-control analysis of overall survival (OS) in routine clinical practice**

M. Faehling, B. Schwenk, M. Kopp, S. Fallscheer, S. Kramberg, R. Eckert; Esslingen, DE

12:30 - 12:30 **164P - PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC**



Y. Qin, L. Jiang, Y. Li, L. Ren, Y. Wang, Y. Gong, F. Peng, J. Zhu, Z. Ding, Y. Liu, M. Yu, Y. Lu, M. Huang; Chengdu, CN

- 12:30 - 12:30 **165P - Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis**
T. Landre¹, G. Des Guetz², A. Vergnenegre³, C. Chouaid⁴; ¹Sevrans, FR, ²Bobigny, CEDEX/FR, ³Limoges, CEDEX/FR, ⁴Créteil, CEDEX 12/FR
- 12:30 - 12:30 **166P - Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a prospective, observational, single institution study**
K. Rounis¹, C. Papadaki¹, D. Makrakis¹, A. Monastirioti¹, L. Vamvakas², K. Kalbakis¹, D. Mavroudis¹, S. Aggelaki¹; ¹Heraklion, GR, ²Heraklion, Crete/GR
- 12:30 - 12:30 **167P - Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer**
B. Rapoport¹, D. Vorobiof², L. Langenhoven³, J. Hall⁴, R. Van Eeden¹, T. Smit¹, S.W. Chan⁵, M. Botha⁶, J. Raats³, M. De Necker⁷, H. Duvenhage⁸; ¹Sandton, ZA, ²Bnei Atarot, Gauteng/IL, ³Cape Town, ZA, ⁴Cape Town, Western Cape/ZA, ⁵Sandton, Gauteng/ZA, ⁶George, Western Cape/ZA, ⁷Pretoria, ZA, ⁸Woodmead, ZA
- 12:30 - 12:30 **168P - Dynamic changes of platelet-to-lymphocyte ratio predict efficacy of PD-1/PD-L1 inhibitors in NSCLC**
F. Zhou, A. Xiong, C. Zhou; Shanghai, CN
- 12:30 - 12:30 **169P_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)**
E. Corral de la Fuente, A. Barquín García, C. Saavedra Serrano, M.E. Olmedo García, R. Martín Huertas, J.J. Serrano Domingo, V. Albarrán Artahona, A. Gómez Rueda; Madrid, ES
- 12:30 - 12:30 **170P - Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade**
W. Nie¹, M. Xu¹, L. Gan¹, Y. Zhang², B. Han¹; ¹Shanghai, CN, ²Chongqing, CN
- 12:30 - 12:30 **171P - Previous exposure to bevacizumab indicated inferior benefits from PD-1/PD-L1 inhibitors in nonsquamous NSCLC**
F. Zhou, Y. Pan, C. Zhou; Shanghai, CN
- 12:30 - 12:30 **172P - A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer**



B. Han¹, K. Li², T. Chu¹, M. Bi³, H. Zhang⁴, Y. Yu⁵, J. Shi⁶, X. Zhang⁷, Z. Chen⁸, C. Han⁹, T. Bai⁹; ¹Shanghai, CN, ²Tianjin, CN, ³Bengbu, CN, ⁴Xi'an, CN, ⁵Harbin, CN, ⁶Linyi, CN, ⁷Qingdao, CN, ⁸Hefei, CN, ⁹Jinan, CN

- 12:30 - 12:30 **173P - Stereotactic radiotherapy concurrent to immune or targeted therapy for oligometastatic NSCLC: Clinical scenarios affecting survival**
S. Kroeze¹, C. Fritz¹, D. Kaul², O. Blanck³, K. Kahl⁴, F. Roeder⁵, S. Siva⁶, J. Verhoeff⁷, A. Grosu⁸, M. Schymalla⁹, M. Glatzer¹⁰, M. Szuets¹¹, M. Geier¹², G. Skazikis¹³, I. Sackerer¹⁴, F. Lohaus¹⁵, F. Eckert¹⁶, M. Guckenberger¹⁷; ¹Zurich, CH, ²Berlin, DE, ³Gustow, DE, ⁴Augsburg, DE, ⁵München, DE, ⁶Melbourne, AU, ⁷Utrecht, NL, ⁸Freiburg, DE, ⁹Marburg, DE, ¹⁰St. Gallen, CH, ¹¹Rostock, DE, ¹²Linz, AT, ¹³Villingen-Schwenningen, DE, ¹⁴Freising, DE, ¹⁵Dresden, DE, ¹⁶Tübingen, DE, ¹⁷Zürich, CH
- 12:30 - 12:30 **174P - NSCLC stages IIa-IIIc: Tumor related IGRT yields better local control than kV-guidance to anatomic structures**
F. Zehentmayr¹, J. Karner¹, K. Wurstbauer², R. Wass³, G. Fastner¹, L. Rettenbacher¹, M. Studnicka¹, C. Pirich¹, P. Kopp¹, F. Sedlmayer¹; ¹Salzburg, AT, ²Feldkirch, AT, ³Linz, AT
- 12:30 - 12:30 **175P - Permanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non-small cell lung cancer (NSCLC)**
M. Martinez Kareaga¹, N. Urbieta-Macazaga², C. Sanchez-Vieco³, L. Tomás-López³, I. Intxaurbe-Etxebarria³, B. Mareque³, N. Torregó³, A. Narro³, L. Puntí³, I. Guillen³; ¹Vitoria-Gasteiz, ES, ²San Sebastian, ES, ³Vitoria, ES
- 12:30 - 12:30 **176P - Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy**
M. Altini¹, I. Massa¹, W. Balzi¹, N. Gentili¹, F. Foca¹, V. Danesi¹, S. Manunta¹, M. Burgio¹, P. Cravero¹, F. Ejzykowicz², S. Chandwani², A. Delmonte¹; ¹Meldola, IT, ²Rahway, NJ/US
- 12:30 - 12:30 **177P - Real-world experience of ALK positive NSCLC from India**
M. Malhotra, V. Noronha, A. Joshi, V. Patil, S. Wadhwa, K. Prabhash; Mumbai, IN
- 12:30 - 12:30 **178P - Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients**
D. Abdulla¹, M. Ruge¹, M. Scheffler¹, L. Nogova², S. Koleczko², T. Persigehl¹, S. Grau¹, A. Drzezga¹, C. Kobe¹, R. Buettner², N. Galldiks¹, J. Wolf¹; ¹Cologne, DE, ²Köln, DE
- 12:30 - 12:30 **179P - Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice**
M. Frueh¹, O. Rahma², R. Pachynski³, J. Mazieres⁴, J. Goldschmidt Jr.⁵, T. Ton⁶, S. Mhatre⁶, C. Chuo⁶, J. Martinalbo⁷, J. Davies⁸, R. Juergens⁹; ¹St. Gallen, CH, ²Boston, MA/US, ³St. Louis, MO/US, ⁴Toulouse, FR, ⁵Blacksburg, VA/US, ⁶South San Francisco, CA/US, ⁷Basel, CH, ⁸Welwyn Garden City, GB, ⁹Hamilton, ON/CA



- 12:30 - 12:30 **180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer**
J. Spicer¹, M. Provencio², P. Garrido Lopez², J. Bosch-Barrera³, F.J. de Castro Carpeño², E. Felip⁴, J. Trigo⁵, S. Viteri⁴, E. Coart⁶, E. Schmidt⁷, A. Christiansen⁸, M. Zocca⁸, M. Andersen⁸, E. Ehrnrooth⁸, L. Paz-Ares²; ¹London, GB, ²Madrid, ES, ³Girona, ES, ⁴Barcelona, ES, ⁵Malaga, ES, ⁶Ottignies, BE, ⁷Kenilworth, NJ/US, ⁸Copenhagen, DK
- 12:30 - 12:30 **181TiP - Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study**
M. Shimokawa¹, K. Nosaki¹, T. Seto², K. Ohashi³, M. Morise⁴, Y. Fujiwara⁵, J. Sakakibara⁶, H. Murakami⁷, S. Yano⁸, M. Satouchi⁹, S. Matsumoto¹⁰, K. Goto¹⁰, K. Yoh¹⁰; ¹Fukuoka, JP, ²Fukuoka, Fukuoka/JP, ³Okayama, JP, ⁴Nagoya, JP, ⁵Tokyo, JP, ⁶Sapporo, JP, ⁷Shizuoka, JP, ⁸Kanazawa, JP, ⁹Akashi, JP, ¹⁰Kashiwa, Chiba/JP
- 12:30 - 12:30 **182TiP - A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study**
P. Paik¹, A. Cortot², E. Felip³, H. Sakai⁴, J. Mazieres⁵, L. Horn⁶, F. Griesinger⁷, R. Bruns⁸, J. Scheele⁸, J. Straub⁸, R. Veillon⁹; ¹New York City, NY/US, ²Lille, FR, ³Barcelona, ES, ⁴Saitama, JP, ⁵Toulouse, FR, ⁶Nashville, TN/US, ⁷Oldenburg, DE, ⁸Darmstadt, DE, ⁹Pessac, FR
- 12:30 - 12:30 **183TiP - A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer**
D. Planchard¹, B. Li², H. Murakami³, R. Shiga⁴, C. Lee⁵, K. Wang⁵, P. Jänne⁶; ¹Villejuif, FR, ²New York, NY/US, ³Shizuoka, JP, ⁴Tokyo, JP, ⁵Basking Ridge, NJ/US, ⁶Boston, MA/US
- 12:30 - 12:30 **184TiP - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC**
L. Nogova¹, F. Malchers¹, A. Hillmer², S. Merkelbach-Bruse¹, A. Pinto¹, C. Woempner¹, R. Riedel³, M. Scheffler³, S. Michels¹, P. De Porre⁴, A. Santiago-Walker⁵, R. Fischer¹, D. Abdulla³, R. Thomas¹, R. Buettner¹, J. Wolf³; ¹Köln, DE, ²Mainz, DE, ³Cologne, DE, ⁴Beerse, BE, ⁵Spring House, US
- 12:30 - 12:30 **185TiP - RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)**
L. Paz-Ares¹, S. Senan², D. Planchard³, L. Wang⁴, A. Cheong⁵, R. Slepatis⁵, M. Nguyen⁵, E. Vokes⁶; ¹Madrid, ES, ²Amsterdam, NL, ³Villejuif, FR, ⁴Shenzhen, CN, ⁵Summit, NJ/US, ⁶Chicago, IL/US
- 12:30 - 12:30 **186TiP - An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial**



F. Gelsomino¹, M. Tiseo², L. Boni³, L. Cavanna⁴, A. Camerini⁵, R. Chiari⁶, C. Verusio⁷, M. Tognetto¹, A. Ardizzoni¹; ¹Bologna, IT, ²Parma, IT, ³Firenze, IT, ⁴Piacenza, IT, ⁵Lido Di Camaiore, (LU)/IT, ⁶Perugia, IT, ⁷Saronno, (VA)/IT

- 12:30 - 12:30 **187TiP - Tumor treating fields concurrent with standard of care therapy for stage IV NSCLC following platinum failure: Phase III LUNAR study**
U. Weinberg¹, O. Farber², M. Giladi², Z. Bomzon², E. Kirson²; ¹Luzern, CH, ²Haifa, IL
- 12:30 - 12:30 **188TiP - Metformin +- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial**
G. Galli¹, D. Signorelli¹, C. Vernieri¹, M. Ganzinelli², M. Moro¹, A. Fabbri¹, E. Tamborini², M. Marabese¹, E. Caiola¹, M. Brogginini¹, L. Hollander¹, R. Gallucci¹, C. Gavazzi¹, A.M. Rizzo², P. Corsetto², G. Pruneri¹, F. de Braud¹, G. Sozzi¹, V. Torri³, M. Garassino¹; ¹Milan, IT, ²Milano, IT, ³No City Provided, NA
- 12:30 - 12:30 **190P - ERGR-TKIs combined with chemotherapy delays intracranial progression in EGFR-mutant lung adenocarcinoma patients**
C. Li, B. Zhang, J. Guo, F. Hu, W. Nie, X. Zheng, Y. Lou, Y. Shen, X. Zhang; Shanghai, CN
- 12:30 - 12:30 **191P - Assessment of toxicity and clinical outcomes with SBRT in lung metastases: A single institute experience**
V. Pareek, Mumbai, IN
- 12:30 - 12:30 **192P - Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis**
A. Raniszewska, E. Rutkowska, R. Sokolowski, J. Domagala-Kulawik; Warsaw, PL
- 12:30 - 12:30 **193P - Management of cN2 NSCLC patients treated with radical radiotherapy: Relapse with or without brain metastases**
F. McKay, S. Ansel, C. Lowrie, P. McLoone, N. Mohammed; Glasgow, GB
- 12:30 - 12:30 **195TiP - Phase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)**
M. Mehta¹, V. Gondi², M. Ahluwalia³, P. Brown⁴; ¹Chicago, IL/US, ²Warrenville, IL/US, ³Cleveland, OH/US, ⁴Rochester, MN/US
- 12:30 - 12:30 **197P - Effect of surgical treatment on the survival in patients with malignant pleural mesothelioma**
R. Baez-Saldana¹, M.T. Marmolejo-Torres², M. Iñiguez-García², J.A. Berrios Mejía², U. Rumbo-Nava², O. Arrieta-Rodríguez²; ¹Ciudad De México, MX, ²Mexico City, MX
- 12:30 - 12:30 **198P - Efficacy of 150 kHz tumor treating fields (TTFields) and cisplatin or pemetrexed for the treatment of mesothelioma cells in vitro**



U. Weinberg¹, M. Munster², K. Gotlib², R. Schneiderman², Y. Porat², T. Voloshin Sela², S. Davidi², A. Shteingauz², N. Kaynan², E. Zeevi², M. Giladi², E. Kirson², A. Kinzel³, Y. Palti²; ¹Luzern, CH, ²Haifa, IL, ³München, DE

- 12:30 - 12:30 **199P - Safety meta-analysis of clinical trials delivering TTFields to the upper torso**
G.L. Ceresoli¹, M. Pless²; ¹Bergamo, IT, ²Winterthur, CH
- 12:30 - 12:30 **200P - Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center**
K. Leventakos¹, J. Helgeson¹, A. Mansfield¹, E. Deering¹, A. Schwecke¹, A. Adjei¹, J. Molina¹, C. Hocum¹, T. Halfdanarson¹, R. Marks¹, K. Parikh¹, K. Pomerleau¹, S. Coverdill², M. Rammage², T. Haddad¹; ¹Rochester, MN/US, ²Cambridge, MA/US
- 12:30 - 12:30 **201P - Psychosocial and financial impact on family of lung cancer patients: A cancer research center experience**
S. GODARA, S. Beniwal; Bikaner, IN
- 12:30 - 12:30 **202P - Information for lung cancer patients and their caregivers: A systematic analysis of the online landscape**
P. Naish¹, E. Purdy²; ¹Cambridge, GB, ²London, GB
- 12:30 - 12:30 **203P - Retrospective study about lung carcinoid: Our experience in a Spanish hospital**
D. Sanchez Cabrero, P. Cruz, J. de Castro, O. Higuera, A. Pertejo, I. Esteban, L. Gutierrez, J. Villamayor, L. Ostios, D. Viñal, J. Miranda; Madrid, ES
- 12:30 - 12:30 **204P - Diagnostic value of concomitant use of radial probe endobronchial ultrasound with guide sheath and transbronchial biopsy in lung cancer**
S.C. Lee¹, S. Kwak², M.S. Park², Y.S. Kim², J. Chang², S.H. Lee², C.H. Han¹, S.M. Lee¹, C.J. Kim¹; ¹Goyang, KR, ²Seoul, KR
- 12:30 - 12:30 **205P - Non-small cell lung cancer in the elderly: A retrospective study comparing first-line treatment with single-agent vs combination chemotherapy vs tyrosine kinase inhibitor**
É. Cipriano, A. Tavares, A. Soares, F. Estevinho, C. Sottomayor; Matosinhos, PT
- 12:30 - 12:30 **206P - Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center**
I. TSIROUPROU, V. Tsartsianidou, S. Papaemmanouil, N. Pastelli, S. Lampaki, E. Eleftheriadou, K. Domvri, T. Kontakiotis, D. Spyrtatos; Thessaloniki (exohi), GR
- 12:30 - 12:30 **207P - Primary mucinous carcinomas of the lung: Clinical characteristics and treatment outcomes**
A. Thottian¹, G. Babu², L. Dasappa², L. Jacob², S. Babu², K.N. Lokesh³, A. Rudresha³, L. Rajeev², S. Saldanha², G. Gv²; ¹Delhi, Delhi/IN, ²Bangalore, IN, ³Bangalore, Karnatka/IN



- 12:30 - 12:30 **208P - Sarcopenia as prognostic factor in lung cancer patients: A systematic review and meta-analysis**
J. Büntzel¹, J. Heinz¹, C. Röver¹, A. Bleckmann¹, C. Bauer², A. Emmert¹; ¹Göttingen, DE, ²Fulda, DE
- 12:30 - 12:30 **209P - Feasibility and utility of transbronchial cryobiopsy in primary lung cancer: Prospective, single arm study**
K. Kirita¹, H. Udagawa², S. Matsumoto¹, K. Yoh¹, S. Niho¹, K. Goto¹; ¹Kashiwa, Chiba/JP, ²Kashiwa, JP
- 12:30 - 12:30 **210TiP - Evaluation of safety and efficacy of minocycline combined with tyrosine kinase inhibitors in patients of EGFR mutated metastatic lung cancer**
A. Thottian¹, G. Babu², L. Dasappa², L. Jacob², S. Babu², K.N. Lokesh³, A. Rudresha³, S. Saldanha², G. Gv², R. Lk²; ¹Delhi, Delhi/IN, ²Bangalore, IN, ³Bangalore, Karnatka/IN
- 13:00 - 14:00 Medscape Oncology - Industry Satellite Symposium Room A**
 Moderation: L. Paz-Ares, Madrid, ES
- 13:00 - 13:10 **Welcome and introduction: Recent practice changing data - What do they mean in the real world?**
L. Paz-Ares, Madrid, ES
- 13:10 - 13:20 **PDL1: To test or not to test?**
K. Kerr, Aberdeen, GB
- 13:20 - 13:35 **Patient case 1: Optimizing therapy based on CCRT suitability**
C. Le Pechoux, Villejuif, CEDEX/FR
- 13:35 - 13:50 **Patient case 2: Optimizing therapy based on CCRT suitability**
J. Vansteenkiste, Leuven, BE
- 13:50 - 14:00 **Panel Discussion and Q&A**



13:00 - 14:00 Pfizer Oncology - Industry Satellite Symposium **Room C**
Moderation: E. Felip, Barcelona, ES

13:00 - 13:05 **Introduction**
E. Felip, Barcelona, ES

13:05 - 13:15 **Where did we start?**
E. Felip, Barcelona, ES

13:15 - 13:35 **Where are we now and what is on the horizon?**
S. Bajjal, Birmingham, GB

13:35 - 13:50 **How can we make balanced treatment decisions for our EGFR+ patients?**
N. Girard, Paris, FR

13:50 - 14:00 **Q&A**
E. Felip, Barcelona, ES

14:30 - 16:00 Molecular board in clinical practice **Room B**
Moderation: E.F. Smit¹, M. Sebastian²; ¹Amsterdam, NL, ²Frankfurt Am Main, DE

14:30 - 14:30 **Session DOI**

14:30 - 14:55 **Do we need a molecular board in our hospital?**
M. Kris, New York, NY/US

14:55 - 15:20 **Biomarkers are a rapidly changing scenario: How to face it**
E. Smit, Amsterdam, NL

15:20 - 15:45 **Facts and myths of liquid biopsy**
N. Normanno, Napoli, IT

15:45 - 16:00 **Q&A**



14:30 - 16:00 Oligometastatic and oligoprogressive disease: A new era? Room A
Moderation: F. Barlesi¹, F. McDonald²; ¹Marseille, CEDEX 20/FR, ²London, GB

14:30 - 14:30 **Session DOI**

14:30 - 14:55 **How to define it? How to treat it?**

A. Dingemans, Maastricht, NL

14:55 - 15:20 **Local treatment in oligoprogressive disease**

F. McDonald, London, GB

15:20 - 15:45 **Treatment algorithms for oligoprogressive and oligometastatic disease**

F. Barlesi, Marseille, CEDEX 20/FR

15:45 - 16:00 **Q&A**



14:30 - 16:00 **Quality of Life (QoL) and care: New paradigms** **Room C**
Moderation: A. Aguarón Turrientes, Brussels, BE

14:30 - 14:30 **Session DOI**

14:30 - 14:35 **Introduction**

A. Aguarón Turrientes, Brussels, BE

14:35 - 14:55 **Is palliative care under threat for stigma? LuCE and Hospice Casa Sperantei initiative for early integration of palliative care interventions in the plan of care of lung cancer patients**

N. Mitrea, Bucharest, RO

14:55 - 15:15 **How accurate are we in measuring quality of life?**

L. Magee, Cambridge, GB

15:15 - 15:35 **Clinical trials: Safety and pharmacovigilance**

D. Villalon, Madrid, ES

15:35 - 15:55 **Supporting lung cancer survivors: Living with and beyond lung cancer**

R.D. Ihlen, Le Relecq Kerhuon, FR

15:55 - 16:00 **Conclusions and perspectives**

A. Aguarón Turrientes, Brussels, BE



14:30 - 16:00	Integrated care in LCC Moderation: A. Fraser, Auckland, NZ	Room K
14:30 - 14:30	Session DOI	
14:30 - 14:35	Introduction <u>A. Fraser</u> , Auckland, NZ	
14:35 - 15:00	Integrating early palliative care to oncology care: Are we there yet? <u>A. Charalambous</u> , Limassol, CY	
15:00 - 15:20	Advance care planning in LC: Practices and challenges <u>M. Connolly</u> , Dublin, IE	
15:20 - 15:45	Patient's experience of the integrated model of care <u>S. Parreira</u> , Lisbon, PT	
15:45 - 16:00	Conclusions and Q&A <u>A. Fraser</u> , Auckland, NZ	
16:00 - 16:30	Coffee break	Hall 1



16:30 - 17:30	AstraZeneca - Industry Satellite Symposium Moderation: V. Papadimitrakopoulou, Houston, US	Room A
16:30 - 16:35	Welcome and programme overview <u>V. Papadimitrakopoulou</u> , Houston, US	
16:35 - 16:45	Considerations for first-line treatment selection for patients with metastatic EGFRm NSCLC <u>M. Garassino</u> , Milan, IT	
16:45 - 16:45	Panel discussion <u>V. Papadimitrakopoulou</u> ¹ , <u>N. Reinmuth</u> ² ; ¹ Houston, US, ² Gauting, DE	
16:45 - 17:00	What do we know? First-line osimertinib treatment and mechanisms of acquired resistance <u>N. Reinmuth</u> , Gauting, DE	
17:00 - 17:00	Panel discussion <u>M. Garassino</u> ¹ , <u>V. Papadimitrakopoulou</u> ² ; ¹ Milan, IT, ² Houston, US	
17:00 - 17:10	What's next? Clinical management of patients with progression on first-line osimertinib <u>V. Papadimitrakopoulou</u> , Houston, US	
17:10 - 17:10	Panel discussion <u>M. Garassino</u> ¹ , <u>N. Reinmuth</u> ² ; ¹ Milan, IT, ² Gauting, DE	
17:10 - 17:25	How do we manage patients who need second-line therapy? Clinical practice approach to therapy selection <u>V. Papadimitrakopoulou</u> , Houston, US	
17:25 - 17:25	Panel discussion <u>M. Garassino</u> ¹ , <u>N. Reinmuth</u> ² ; ¹ Milan, IT, ² Gauting, DE	
17:25 - 17:30	Conclusions <u>V. Papadimitrakopoulou</u> , Houston, US	



16:30 - 17:30 Bayer - Industry Satellite Symposium **Room C**
Moderation: L. Bubendorf, Basel, CH

16:30 - 16:35 **Welcome and introduction**
L. Bubendorf, Basel, CH

16:35 - 16:50 **Emerging data on TRK inhibition in TRK fusion lung cancer**
A. Drilon, New York, NY/US

16:50 - 17:05 **Testing for TRK fusion lung cancer**
L. Bubendorf, Basel, CH

17:05 - 17:15 **Ask the experts: Patient cases from TRK inhibitor clinical trials**
L. Bubendorf¹, A. Drilon²; ¹Basel, CH, ²New York, NY/US

17:15 - 17:30 **Q&A and close**
L. Bubendorf¹, A. Drilon²; ¹Basel, CH, ²New York, NY/US

16:30 - 18:00 Novel interventions in LC **Room K**
Moderation: A. Molassiotis¹, A. Fraser²; ¹Shatin, Pokfulam/HK, ²Auckland, NZ

16:30 - 16:30 **Session DOI**

16:30 - 16:35 **Introduction**
A. Fraser, Auckland, NZ

16:35 - 16:55 **Patient reported-outcomes: Where nursing fits**
C. de los Rios de la Serna, Southampton, GB

16:55 - 17:15 **Management of patients with peripheral neuropathy**
A. Fraser, Auckland, NZ

17:15 - 17:35 **Management of cough in patients with LC**
A. Molassiotis, Shatin, Pokfulam/HK

17:35 - 17:55 **Supporting lung cancer patients through virtual environments**
A. Ioannou, Strovolos, CY

17:55 - 18:00 **Conclusions**
A. Molassiotis, Shatin, Pokfulam/HK



- 17:45 - 18:45 Mini Oral session III** **Room C**
Moderation: W. Eberhardt¹, M. Guckenberger², J. Zugazagoitia³; ¹Essen, DE, ²Zürich, CH, ³New Haven, US
- 17:45 - 17:45 **Session DOI**
- 17:45 - 17:50 **20 - Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC**
G. Mazzaschi¹, F. Quaini¹, G. Milanese¹, D. Madeddu¹, G. Bocchialini², L. Ampollini¹, L. Gnetti¹, C. Lagrasta¹, M. Silva¹, G. Roti¹, N. Sverzellati¹, M. Tiseo¹; ¹Parma, IT, ²Parma, Parma/PR/IT
- 17:50 - 17:55 **420 - Implementation of organized lung cancer screening program in Korea**
Y. Kim, Gyeonggi, KR
- 17:55 - 18:00 **430 - Baseline results from a French pilot study on lung cancer screening by CT scan: DEP KP80**
O. Leleu¹, M. Auquier², B. Chauffert³, P. Berna², V. Petigny², A. Ait Addi², D. Basille², V. Jounieaux²; ¹Abbeville, FR, ²Amiens, FR, ³Amiens, CEDEX/FR
- 18:00 - 18:05 **700 - Radiomic-based quantitative CT analysis to predict the invasiveness of pure ground-glass lung adenocarcinoma**
F. Xv¹, W. Zhu², H. Hu²; ¹Hangzhou, CN, ²Hangzhou, CN
- 18:05 - 18:10 **710 - Impact of underlying pulmonary diseases on treatment outcomes in early stage non-small cell lung cancer treated with definitive radiotherapy**
H. Kim, H. Yoo, H. Pyo, H.Y. Park; Seoul, KR
- 18:10 - 18:15 **720 - Multi-centre analysis of cardiac events following radical radiotherapy for lung cancer**
F. Sun¹, K. Banfill², J. Lilley³, B. Wheller³, L. Murray³, A. McWilliam², M. Van Herk², A. Abravan², C. Faivre-Finn², K. Franks⁴; ¹Cottingham, East Yorkshire/GB, ²Manchester, GB, ³Leeds, GB, ⁴Leeds, Yorkshire/GB
- 18:15 - 18:20 **860 - The effect of prophylactic cranial irradiation (PCI) for young stage III NSCLC patients: Subgroup analyses of the NVALT-11/DLCRG-02 study**
W. Witlox¹, B. Ramaekers¹, H. Groen², A. Dingemans¹, J. Praag³, J. Belderbos⁴, V. Van der Noort⁴, H. Van Tinteren⁴, M. Joore¹, D. De Ruyscher¹; ¹Maastricht, NL, ²Groningen, NL, ³Rotterdam, NL, ⁴Amsterdam, NL
- 18:20 - 18:25 **1200 - Thromboembolic events in advanced non-small cell lung cancer**



V. Srinivasalu¹, N. Subramaniam², S. Raghuram², S. Kolathu², B. Ponnada², A. Philip³, W. Jose⁴, K. Pavithran⁴; ¹Bangalore, IN, ²Kochi, IN, ³Cochin, Tamil Nadu/IN, ⁴Kochi, Kerala/IN

18:25 - 18:45 **Discussion led by moderators**

17:45 - 18:45 Should sequencing of ALK inhibitors be molecularly-guided? Room A
Moderation: T. Newsom-Davis¹, D. Planchard²; ¹London, GB, ²Villejuif, FR

17:45 - 17:45 **Session DOI**

17:45 - 17:55 **Introduction and first vote**
T. Newsom-Davis, London, GB

17:55 - 18:15 **Yes**
A. Shaw, Boston, MA/US

18:15 - 18:35 **No**
N. Girard, Paris, FR

18:35 - 18:45 **Second vote and conclusions**
D. Planchard, Villejuif, FR



13.04.2019

08:00 - 09:30 SCLC: New targets **Room A**
Moderation: S. Popat¹, S. Ekman²; ¹London, GB, ²Stockholm, SE

08:00 - 08:00 **Session DOI**

08:00 - 08:20 **Molecular targets and therapies for SCLC**
S. Ekman, Stockholm, SE

08:20 - 08:40 **Immune targets and therapies for SCLC**
E. Felip, Barcelona, ES

08:40 - 09:00 **Genomics of SCLC: Therapeutically relevant advances**
M. Peifer, Cologne, DE

09:00 - 09:20 **What can mice tell us about drugging SCLC?**
A. Berns, Amsterdam, NL

09:20 - 09:30 **Q&A**

08:30 - 09:30 Do we treat patients with I-O until progression? **Room C**
Moderation: S. Peters¹, D. Planchard²; ¹Lausanne, CH, ²Villejuif, FR

08:30 - 08:30 **Session DOI**

08:30 - 08:40 **Introduction and first vote**
S. Peters, Lausanne, CH

08:40 - 09:00 **I-O until PD**
D. Spigel, Nashville, TN/US

09:00 - 09:20 **I-O fixed-time duration**
F. de Marinis, Milan, IT

09:20 - 09:30 **Second vote and conclusions**
D. Planchard, Villejuif, FR



09:40 - 11:10 Mesothelioma **Room A**
Moderation: S. Novello¹, L. Greillier²; ¹Orbassano, IT, ²Marseille, FR

09:40 - 09:40 **Session DOI**

09:40 - 10:00 **Epidemiology and asbestos ban: European picture**

L. Greillier, Marseille, FR

10:00 - 10:20 **Potential biomarkers for MPM in asbestos-exposed subjects**

F. Galateau-Sallé, Lyon, FR

10:20 - 10:40 **Treatment of localised disease**

H. Pass, New York, NY/US

10:40 - 11:00 **Novel targets, new therapeutic strategies and future perspectives**

N. Van Zandwijk, Concord, NSW/AU

11:00 - 11:10 **Q&A**

09:40 - 11:10 Optimal management of brain metastases in NSCLC **Room C**
Moderation: N. Leigh¹, M. Weller²; ¹Toronto, CA, ²Zurich, CH

09:40 - 09:40 **Session DOI**

09:40 - 10:00 **Is there still a role for surgery?**

M. Weller, Zurich, CH

10:00 - 10:20 **The role of brain irradiation**

C. Faivre-Finn, Manchester, GB

10:20 - 10:40 **Sequencing systemic therapy without driver mutations**

N. Leigh, Toronto, CA

10:40 - 11:00 **Sequencing systemic therapy with driver mutations**

E. Arriola Aperribay, Barcelona, ES

11:00 - 11:10 **Q&A**



11:10 - 11:30	Coffee break	Foyer
11:30 - 12:00	Overcoming resistance to immune checkpoint inhibitors Moderation: G. Scagliotti, Orbassano, TO/IT	Room A
11:30 - 11:30	Session DOI	
11:30 - 12:00	Overcoming resistance to immune checkpoint inhibitors <u>W. Fridman</u> , Paris, FR	
12:00 - 12:15	Closing remarks Moderation: P. Garrido Lopez ¹ , J. Wolf ² ; ¹ Madrid, ES, ² Cologne, DE	Room A
12:00 - 12:00	Session DOI	